UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 1 of 59 Activated:  08/08/2014  Current Version : Amendment 2  Date:  6/25/15  
Closed:   History:  Initial  Date:  7/09/14 
 
 
 
 
A Phase I clinical trial to determine the safety and tolerability of UC -961 (Cirmtuzumab), 
an anti -ROR1 monoclonal antibody, for the treatment of patients with relapsed or 
refractory Chronic Lymphocytic Leukemia who are ineligible for chemotherapy  
 
 
 
PRINCIPAL INVESTIGAT ORS  
Catriona Jamieson, MD/PhD  
Hematology/Oncology  
3855 Health Sciences Drive, #0820  
La Jolla, CA 92093 -0987  
Phone: 858 -534-7128  
Fax: 858 -822-6288  
Email:  cjamieson@ucsd.edu  Michael Choi, MD (Co -PI) 
Hematology/Oncology  
3855 Health Sciences Drive, #0820  
La Jolla, CA 92093 -0820  
Phone: (858) 534 -1765  
Fax: (858) 534 -5620  
Email: mychoi@ucsd.edu  
 
 
Protocol Number:   HRPP #140141  
 
Investiga tional Product:  UC-961 (Cirmtuzumab)  
 
IND Number:    117975  
 
IND Holder:    Thomas Kipps, MD/PhD   
 
 
NCT Number:    02222688  
 
 
 
 
 
 
 
 
 
 
 
 
Confidential  
This material is the property of the Moores Cancer Center and the University of California, San Diego. Do 
not disclose or use except as authorized in writing by UC San Diego.  
  

UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 2 of 59 LIST OF INVESTIGATORS  
 
 
PRINCIPAL INVESTIGATORS  
Catriona Jamieson, MD/PhD  
Hematology/Oncology  
3855 Health Sciences Drive, #0820  
La Jolla, CA 92093 -0987  
Phone: 858 -534-7128  
Fax: 858 -822-6288  
Email:  cjamieson@ucsd.edu  
 
Michael Choi, MD (Co -PI) 
Hematology/Oncology  
3855 Health Sciences Drive, #0820  
La Jolla, CA 92093 -0820  
Phone: (858) 534 -1765  
Fax: (858) 534 -5620  
Email: mychoi@ucsd.edu  STUDY STATISTICIANS  
Karen Messer, PhD  
Biostatistics  
3855 Hea lth Sciences Drive, #0901  
La Jolla, CA 92093 -0901  
Phone:  858-822-4334  
Email:  kmesser@ucsd.edu  
 
Hongying Li, PhD  
Biostatistics  
3855 Health Sciences Drive, #0901  
La Jolla, CA 92093 -0901  
Phone: 858 -822-4818  
Email: hol031@ucsd.edu  
 
 
 
CO-INVESTIGATOR(S)  
Januario Castro, MD  
Hematology/Oncology  
3855 Health Sciences Drive, #0960  
La Jolla, CA 92093 -0960  
Phone: 858 -822-6386  
Fax: 858-822-6844  
Email:  jecastro@ucsd.edu  
 Thomas Kipps, MD/PhD  
Hematology/Oncology  
3855 Health Sciences Drive, #0820  
La Jolla, CA 92093 -0820  
Phone:  858-534-5400  
Fax: 858-534-5620  
Email:  tkipps@ucsd.edu  
 
Dennis Carson, MD  
Medicine  
9500 Gilman Drive #0695  
La Jolla, CA 92093 -0695  
Phone:  858-534-5408  
Fax: 858-246-1586  
Email:  dcarson@ucsd.edu   
 
 
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 3 of 59  
Signature Page  
 
 
The signature below constitutes the approval of this protocol and the attachments, and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local  legal and 
regulatory requirements and applicable U.S. federal regulations and ICH guidelines.  
 
 
 
Principal Investigator (PI) Name: _____________________________  
 
 
 
PI Signature: _____________________________  
 
 
 
Date: ____________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 4 of 59 TABLE OF CONTENTS  
LIST OF INVESTIGATOR S ................................ ................................ ................................ ..........................  2 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ..............................  6 
SCHEMA  ................................ ................................ ................................ ................................ .....................  11 
1.0 BACKGROUND  ................................ ................................ ................................ ................................  11 
1.1 INTRODUCTION /RATIONALE FOR DEVELOPMENT  ................................ ................................ ................  11 
1.2 UC-961 DEVELOPMENT AND PRECL INICAL ACTIVITY IN CLL  MODELS  ................................ ..................  12 
1.3 RATIONALE FOR DOSE SELECTION  ................................ ................................ ................................ .... 14 
1.4 OVERVIEW OF PROPOSED STUDY  ................................ ................................ ................................ ..... 15 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ .......................  16 
3.0 PATIENT ELIGIBILITY  ................................ ................................ ................................ ......................  17 
3.1 INCLUSION CRITERIA  ................................ ................................ ................................ ........................  17 
3.2 EXCLUSION CRITERIA  ................................ ................................ ................................ .......................  18 
4.0 INVESTIGATIONAL TREA TMENT PLAN  ................................ ................................ ........................  20 
4.1 DOSE ASSIGNMENT ................................ ................................ ................................ ..........................  20 
4.2 DOSE LIMITING TOXICITY  ................................ ................................ ................................ ..................  21 
4.3 RECOMMENDED PRE-MEDICATIONS AND CONCOMITANT MEDICATIONS  ................................ ..............  22 
4.4 UC-961 INFUSION PLAN  ................................ ................................ ................................ ...................  22 
4.5 CRITERIA FOR STARTING SUBSEQUENT CYCLES  ................................ ................................ ................  25 
4.6 DOSE MODIFICATIONS AND DOSING DELAYS  ................................ ................................ .....................  25 
4.7 PERMITTED CONCOMITANT  THERAPY  ................................ ................................ ................................ . 30 
4.8 PROHIBITED CONCOMITAN T THERAPY  ................................ ................................ ................................  30 
4.9 DURATION OF THERAPY  ................................ ................................ ................................ ...................  30 
4.10 DURATION OF FOLLOW UP ................................ ................................ ................................ .............  31 
4.11 CRITERIA FOR REMOVAL FROM STUDY  ................................ ................................ ............................  31 
5.0 STUDY PROCEDURES  ................................ ................................ ................................ ....................  31 
5.1 SCREENING /BASELINE PROCEDURES  ................................ ................................ ................................  31 
5.2 TO BE COMPLETED ON DAY 1 OF ALL CYCLES  ................................ ................................ ....................  32 
5.3 TO BE COMPLETED ON DAY 2 AND DAY 8 OF EACH CYCLE  ................................ ................................ .. 33 
5.4 TO BE COMPLETED ON DAY 3 AND DAY 10 OF CYCLE 1 (AND ANY ADDITIONAL C YCLES WHEN THE DOSE 
LEVEL CHANGES DURING  INTRA -PATIENT DOSE ESCALAT ION) ................................ ................................ ....... 33 
5.5 END OF TREATMENT SAFE TY ASSESSMENT 28 DAYS AFTER FINAL INFU SION (+/- 3 DAY) .......................  33 
5.6 RESPONSE ASSESSMENT 56 DAYS AFTER FINAL IN FUSION (+/- 3 DAY), ................................ ...............  34 
5.7 LONG TERM FOLLOW -UP ................................ ................................ ................................ ...................  34 
5.8 PHARMACOKINETIC (PK)  STUDIES  ................................ ................................ ................................ .... 34 
5.9 CORRELATIVE STUDIES  ................................ ................................ ................................ ....................  39 
6.0 SCHEDULE OF EVENTS  ................................ ................................ ................................ ..................  41 
7.0 MEASUREMENT OF EFFEC T................................ ................................ ................................ ..........  45 
7.1 SAFETY /TOLERABILITY  ................................ ................................ ................................ .....................  45 
7.2 RESPONSE CRITERIA FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA  ................................ .... 46 
8.0 ADVERSE EVENTS  ................................ ................................ ................................ ..........................  47 
8.1 ADVERSE EVENT MONITORING  ................................ ................................ ................................ .........  47 
8.2 SEVERITY  ................................ ................................ ................................ ................................ ........  48 
8.3 SERIOUSNESS  ................................ ................................ ................................ ................................ . 48 
8.4 RELATIONSHIP  ................................ ................................ ................................ ................................ . 49 
8.5 PRIOR EXPERIENCE ................................ ................................ ................................ ..........................  49 
8.6 REPORTING REQUIREMENTS FOR ADVERSE EVENTS  ................................ ................................ .........  49 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 5 of 59 9.0 AGENT INFORMATION  ................................ ................................ ................................ ....................  50 
9.1 UC-961 (CIRMTUZUMAB ) ................................ ................................ ................................ .................  50 
10.0 STATISTICAL CONSIDER ATIONS  ................................ ................................ ................................  51 
10.1 STUDY DESIGN /STUDY ENDPOINTS  ................................ ................................ ................................  51 
10.2 STATISTICAL DESIGN  ................................ ................................ ................................ .....................  51 
10.3 EVALUABLE COHORT AND SUBJECT REPLACEMENT  ................................ ................................ .........  52 
10.4 STATISTICAL ANALYSIS  ................................ ................................ ................................ ..................  53 
10.5 EXPOSURE -RESPONSE MODELING ................................ ................................ ................................ ... 53 
11.0 STUDY MANAGEMENT  ................................ ................................ ................................ .................  55 
11.1 CONFLICT OF INTEREST ................................ ................................ ................................ ..................  55 
11.2 INSTITUTIONAL REVIEW BOARD (IRB)  APPROVAL AND CONSENT  ................................ ......................  55 
11.3 SUBJECT DATA PROTECTION  ................................ ................................ ................................ ..........  55 
11.4 DATA AND SAFETY MONITORING  ................................ ................................ ................................ ..... 56 
11.5 RECORD RETENTION ................................ ................................ ................................ ......................  56 
11.6 OBLIGATIONS OF INVESTIGATORS  ................................ ................................ ................................ ... 56 
12.0 REFERENCES  ................................ ................................ ................................ ................................  58 
13.0 APPENDICES  ................................ ................................ ................................ ................................ . 59 
13.1 APPENDIX A. PERFORMANCE STATUS  ................................ ................................ .............................  59 
 
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 6 of 59 PROTOCOL SYNOPSIS  
 
INVESTIGATIONAL 
AGENT  UC-961 
TITLE  A Phase I clinical trial to determine the safety and tolerability, of UC -961 
(Cirmtuzumab), an anti -ROR1 monoclonal antibody, for the treatment of 
patients with relapsed or refractory Chronic Lymphocytic Leukemia who 
are ineligible for chemotherapy  
 
PROTOCOL NUMBER  HRPP #140141  
PHASE OF 
DEVELOPMENT  Phase I  
STUDY OBJECTIVES  Primary Objective:   
1. To determine the maximum tolerated dose (MTD) or biologically 
active dose of UC -961 when given bi -weekly for 4 doses  to 
patients with relapsed or refractory c hronic lymphocytic leukemia 
(CLL).  
Secondary Objectives:  
1. To determine the safety and tolerability of UC -961 by ongoing 
evaluation of adverse events (AEs).    
2. To assess clinical activity based on international working group 
guidelines (iwCLL 2008).  
3. To assess clinical activity by evaluating progression free survival.  
Exploratory Objectives:   
1. To assess the mechanism of action of UC -961 through 
immunophenotypic, genomic, proteomic and pharmacodynamic 
studies.  
STUDY ENDPOINTS  Primary Endpoint  
Rate of dose limiting toxicities (DLTs) and the maximum tolerated dose or 
biologically active dose.  
Secondary Endpoints  
1. Treatment -emergent adverse events (description, timing, grade 
[CTCAE v4.03], severity, seriousness, and relatedness)  
2. Clinical response rate, determined by International Working Group in 
CLL (iwCLL) criteria.  
3. Progression free survival, as determined by iwCLL criteria  
Exploratory Endpoints  
1. ROR1 receptor density on circulating bulk tumor cells and leukemia 
stem cells (immunophenotypic assay)  
2. Plasma pharmacokinetics of UC -961  
3. Level of circulating antibodies against UC -961 
4. Multiplexed assays of focused CLL signaling pathways via qPCR array 
and targeted sequencing.  
5. ROR1 related Protein assays via western blot and quantitative 
proteomics.  
STUDY  DESIGN  This is a first in human phase I study of UC -961, a humanized anti -ROR1 
monoclonal antibody, for patients with relapsed or refractory CLL. As this is 
a Phase 1 study for safety, no formal sample size or power calculations will 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 7 of 59 be made and the 3+3 p hase I dose escalation trial design will be used.  
The starting dose is 15 µg/kg. There is intra -patient dose escalation in the 
first 4 cohorts, followed by the standard 3+3 design for the next 5 cohorts 
until an MTD or biologically active dose is reached.  If there is a grade ≥ 2 
adverse event in the cohorts with intra -patient dose escalation, the trial will 
switch to the standard 3+3 design without intra -patient dose escalation for 
all cohorts. An expansion cohort of 6 patients at that dose will also be 
examined, so that a total of 12 patients will be evaluable at the MTD or 
biologically active dose.  
NUMBER OF PATIENTS  The trial may be completed after 33 patients have been enrolled, based on 
8 cohorts with a total of 12 patients at the MTD/biologically active dose. If 
the dose escalation switches to standard 3+3 design, then up to 78 
patients will be enrolled, based on 3 -6 patients per cohort for 12 cohorts (if 
all dose levels require cohorts without intra -dose escalation), and a total of 
12 patients at the MTD/biologically active dose.  
INCLUSION CRITERIA  1. Ability to understand and the willingness to sign a written informed 
consent.  
2. Clinical and phenotypic verification of B cell CLL and measurable 
disease. Immunophenotyping of the leukemic cells (blood or  marrow) 
must demonstrate a monoclonal (or light chain positive) B cell 
population with immunophenotype consistent with CLL (e.g., co -
expressing CD19 and CD5).  
3. Relapsed or refractory disease, defined by failure to achieve a partial 
response within 6 months  of initiation of therapy, or a 50% increase of 
baseline disease measurements after achieving a clinical response.  
4. Not amenable to approved therapies.  
5. Prior Therapy: Must have progressed after purine -analog or alkylator 
based therapy, or be considered inap propriate for chemo -
immunotherapy due to one of the following:  
 Del 17p, which is associated with poor response to chemo -
immunotherapy, or  
 Age greater than 70, or  
 Age greater than 65 with one of the following:  
o Grade  3 neutropenia, anemia, or thrombocytopenia 
attributable to cumulative myelotoxicity from prior 
administration of cytotoxic agents (as documented by 
bone marrow biopsy obtained since last prior therapy), or  
o Clinically apparent autoimmune cytopenia which ma y be 
exacerbated by fludarabine therapy, or  
o Estimated creatinine clearance (eC Cr) <70 mL/min (as 
determined by the Cockcroft -Gault method), or  
o ECOG performance status greater than 0.  
6. Has recovered from the toxic effects of prior therapy to their clinical 
baseline.  
7. Subjects must be aged 18 years or older.  
8. Both men and women of all races and ethnic groups are eligible for 
this trial.  
9. Women of childbearing potential (not postmenopausal for at least one 
year or not surgically incapable of bearing children) must agree not to 
become pregnant for the duration of the study. Both men and women 
must agree to use a barrier method of contraception for the duration of 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 8 of 59 the study and until 10 weeks after the final dose of UC -961 (expected 
to be greater than 5 half -lives from pre -clinical data).  
10. Subjects must have at least one of the following indications for 
treatment:  
 Symptomatic or progressive splenomegaly;  
 Symptomatic lymph nodes, nodal clusters, or progressive 
lymphadenopathy;  
 Progressive anemia (hemoglobin ≤ 11 g /dL);  
 Progressive thrombocytopenia (platelets ≤ 100 x 109/L);  
 Weight loss > 10% body weight over the preceding 6 month 
period;  
 Fatigue attributable to CLL;  
 Fever or night sweats for > 2 weeks without evidence of 
infection;  
 Progressive lymphocytosis with  an increase of > 50% over a 2 -
month period or an anticipated doubling time of less than 12 
months.  
11. Subjects must have an ECOG performance status of 0 -2.  
12. Adequate hematologic function:   
 Platelet count   50,000/µL unless due to heavily infiltrated 
bone marrow (> 80% CLL cell infiltrate); AND  
 Hemoglobin  8.0 g/dL (may be supported by erythropoietin); 
AND  
 Absolute neutrophil count > 1000 /uL unless due to heavily 
infiltrated bone marrow (> 80% CLL cell in filtrate).  
13. Adequate renal function:  
 Serum creatinine <1.5 times upper limit of normal; OR  
 Calculated Creatinine clearance (CrCl) ≥ 40 mL/min (based 
upon the Cockcroft -Gault Equation [CrCl = (140 -age) * actual 
wt (in kg) * (0.85 if female) / (72 * Cr)].  
14. Adequate hepatic function:  
 Total bilirubin ≤ 2.5 times upper limit of normal; AND  
 ALT ≤ 2.5 times upper limit of normal.  
15. Adequate coagulation tests:  
 Prothrombin time international normalized ratio (INR) ≤ 2; AND  
 Partial thromboplastin time ≤ 1.66 times upper limit of normal.  
EXCLUSON CRITERIA  1. Pregnant or breast -feeding women will not be entered on this study 
due to risks of fetal and teratogenic adverse events as seen in 
animal/human studies. IgG may cross the placental barrier and cause 
fetal B - and T -lymphocyte depletion. Therefore, women of child-
bearing age must obtain a pregnancy test, and pregnant or breast 
feeding females are excluded.  
2. Patients who are currently receiving another investigational agent are 
excluded.  
3. Patients who have had chemotherapy (e.g., purine analogues, 
alkylating ag ents), immunotherapy, radiation therapy, or participation in 
any investigational drug treatment within 4 weeks of initiation of UC -
961 or at any time during the study.  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 9 of 59 4. Patients who have had prior (within 8 weeks of initiation of UC -961) or 
concurrent antib ody therapy directed against CLL (i.e., Rituxan® and 
Campath ®) 
5. Current infection requiring parenteral antibiotics.  
6. Active infection with HIV, HBV, or HCV.  
7. Concurrent malignancy or prior malignancy within the previous 3 years 
(other than completely resect ed carcinoma in situ, prostate cancer, or 
localized non -melanoma skin cancer).  
8. Known central nervous system (CNS) involvement by malignancy.  
9. Untreated autoimmunity such as autoimmune hemolytic anemia, or 
immune thrombocytopenia.  
10. Known u ncompensated hypot hyroidism (defined as TSH greater than 
2x upper limit of normal not treated with replacement hormone).  
11. Presence of more than 55% pro -lymphocytes in peripheral blood. 
Patients with Richter’s transformation are not excluded.  
12. Insufficient recovery from surgi cal-related trauma or wound healing.  
13. Impaired cardiac function including any of the following:  
 Myocardial infarction within 6 months of starting study drug;  
 A past medical history of clinically significant ECG abnormalities, 
including QTc 481 ms  or greater.  
 Other clinically significant heart disease (e.g. congestive heart 
failure, uncontrolled hypertension, history of labile hypertension, or 
history of poor compliance with an antihypertensive regimen)  
14. Patients who in the opinion of the investigat or may be unable to 
comply with the safety monitoring requirements of the study.  
DURATION OF 
INVESTIGATIONAL 
AGENT 
ADMINISTRATION AND 
STUDY 
PARTICIPATION  Duration of UC -961 administration is 8 weeks, consisting of 4 doses of UC -
961, given once every 14 d ays. Patients may remain on the clinical trial 
protocol until one of the following:  
 Clinical or radiographic progressive disease (See Section 12).  
 Adverse Events requiring removal from study (See Section 13).  
 Refusal of further protocol therapy by patient/parent/guardian  
 Non-compliance that in the opinion of the investigator does not 
allow for ongoing participation.  
 Physician determines it is in the patient’s best interest to 
discontinue participation in the clinical trial.  
 Completion of all clinica l trial procedures.  
 
Participation in the study and long -term follow -up will continue until one of 
the following:  
 Death.  
 Loss to follow -up. 
 Withdrawal of consent for any further data submission.  
 Progression requiring initiation of subsequent therapy.  
STUD Y DRUG 
ADMINISTRATION  UC-961 is administered by intravenous infusion on Day 1 of each 14 day 
cycle. The initial dose level is 15 µg/kg, based on preclinical studies.  
CRITERIA TO 
EVALUATE SAFETY  Safety will be determined by Principal Investigator, and will be assessed 
according to the NCI Common Terminology Criteria for Adverse Events 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 10 of 59 version 4.03 (NCI CTCAE v4.03) for non -hematologic toxicity and modified 
iwCLL criteria for hematologic toxicity.    
CRITERIA TO 
EVALUATE EFFICACY  Clinical response rate is the percentage of patients meeting criteria for 
partial response, nodular partial response, or complete response based on 
iwCLL criteria. Progression free survival is according to iwCLL definition .  
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 11 of 59 SCHEMA  
 
 
1.0 BACKGROUND  
1.1 Introduction/Rationale for Development  
Chronic Lymphocytic Leukemia (CLL) is the most prevalent hematologic cancer in the western 
hemisphere (Gribben and O'Brien, 2011 ). At this time, it is considered incurable. Treatment 
regimens that combine chemotherapy and immunotherapy (eg: Fludarabine + Cyclophosphamide 
+ Rituximab) have produced high response rates and have been associated with an improved 
overall survival (Hallek et al., 2010) . However, patients inevitably relapse and many patients 
cannot tolerate chemoimmunotherapy regimens in the relapsed/refractory setting due to age, 
comorbidities, or compromised bone marrow function (Brown, 2011) . Obinutuzumab (GA -101) in 
combination with chlorambucil was approved by the FDA in November 2013 based on efficacy as 
front-line therapy for patient s older than 65.  However, responses were not durable with this 
treatment either (Goede et al. , 2014) .  
 
Ibrutininb, an oral agent that inhibits the B -cell receptor associated tyrosine kinase, Bruton’s  
tyrosine kinase (BTK), has been approved by the FDA for the treatment of patients with relapsed 
CLL (Byrd et al., 2013) . According to the package insert, the overall response rate is 58.3%, 
consisting of partia l responses with no complete responses and duration of response ranging 
from 5.6 to 24.2 months .  Ibrutinib intolerance related to diarrhea in 62% of patients and 
thrombocytopenia in over 20% of patients with bleeding events in 63% of patients and subdural  
hematomas in 4% of patients, infections, fatigue, renal insufficiency and other side effects have 
limited the number of patients amenable to chronic therapy. In addition, disease progression 
associated with resistance to ibrutinib has been noted to develo p over time.  Emergence of 
mutations in leukemia initiating cells renders patients resistant to ibrutinib therapy  (Woyach et al. , 
2014) . Thus, to maximize the therapeutic potential of tyrosine kinase and other  inhibitors, to 
prevent therapeutic resistance, and to obviate relapse, development of combination therapies has 
become the mainstay of recent CLL eradication strategies.  Thus, development and testing of 
novel therapeutic strategies, such as UC -961, which selectively target tumor initiating cells in CLL, 
are warranted.  
 
ROR1 ( receptor tyrosine kinase -like orphan receptor 1) is a transmembrane protein that is 
expressed on the surface of CLL cells, from nearly all patients with CLL (94% based on flow 
cytometr y analysis of the CLL research consortium) (Fukuda et al., 2008) . It shares homology 
with other receptor tyrosine kinases, and is believed to participate in Wnt signaling, based on 
homology to the Wnt receptor, Frizzled. However, its precise function is unknown, and although 
the protein has a putative kinase domain, it may be a pseudo -kinase serving as a cofactor for 
other signaling proteins, leading to phosphorylation of Akt.  
Screening and 
Consent: 
Relapsed/
Refractory 
CLLUC-961 Treatment
q 14 days x 4 dosesResponse 
Asse ssme nt
2 month post txday 1       15              29               43         
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 12 of 59  
Import antly, ROR1 is not expressed on the surface of normal adult tissues, with the possible 
exception of a rare subset of precursor B cells, called hematogones, which are typically observed 
in the marrow of pediatric patients or patients recovering from myeloab lative therapy, but are 
found in minute levels (<1% of mononuclear cells) in the marrow of healthy adults (Broome et al., 
2011) . ROR1 plays a key role in fetal development, but based on exhaustive prof iling studies in 
human hematopoietic stem cells, it is no longer detectable by the second trimester fetal liver 
stage, and is not on marrow stem cells or normal adult tissues (Fukuda et al., 2008, Hudecek et 
al., 2010, Masiakowski and Carroll, 1992,  Matsuda et al., 2001, Zhang et al., 2012) . As such, it 
represents an ideal target for immunotherapy, due to a potential lack of cross -reactivity with 
normal adult tissues, reduced immunosuppression based on lack of targeting or normal myeloid 
or lympho id cells.  
 
UC-961 (Cirmtuzumab) is a fully -humanized monoclonal antibody designed to bind the 
extracellular immunoglobulin -like domain of ROR1 with high -affinity. Initial preclinical studies 
(described below) show that it is an ideal potential therapy due to the following features:  
 High affinity for cell -surface ROR1  
 Activity against cancer cells that express ROR1, which include cancer -stem cells, with 
a mechanism of cell death that appears to be due to inhibition of Wnt5a/ROR1 
mediated Akt signaling and no n-canonical Wnt signaling, both important pathways for 
the survival of CLL cells (Fukuda et al. , 2008, Cui et al. , 2013, Widhopf et al. , 2014) . 
 Lack of cross reactivity with normal adult tissues  
 Reduced immunosuppressive potential based on lack of targeting most normal 
lymphoid or myeloid cells  
 Low immunogenic potential due to subst antial humanization of the mAb framework  
 
Based on this biological rationale and the preclinical activity, an open label, phase I clinical trial is 
proposed herein to evaluate the safety and efficacy of UC -961 for the treatment of patients with 
relapsed or  refractory CLL.  
 
1.2 UC-961 Development and preclinical activity in CLL models  
UC-961 is the result of testing and optimization of anti -human ROR1 monoclonal antibodies 
initially generated by classical hybridoma and phase display technologies. Initially, mice  were 
inoculated with DNA, protein, adenoviral constructs of ROR1, cytokines, and immune stimulatory 
agents to generate anti -human ROR1 antibodies. These initial murine anti -ROR1 monoclonal 
antibodies (designated 4A5 and D10) have been tested using in vivo  and in vitro  test systems.  
When tested in an immune deficient murine model, D10 consistently demonstrated potent activity 
against human CLL patient samples. At this time, the D10 mAb has been tested against human 
primary CLL cells in hundreds of mice and  has consistently eliminated the human cells in a dose 
dependent manner. Mouse models have included immune -deficient mice with CLL cell 
xenografts, as well as immune competent transgenic models that spontaneously generate 
leukemic cells expressing the huma n ROR1 protein. In these models, the D10 mAb, but not 
control IgG or 4A5, was able to inhibit the development and expansion of the ROR1 positive 
leukemic B cells in the blood and spleen of recipient animals. A dose of 10 mg/kg was used.  
 
To improve binding  affinity, chimeric truncated ROR1 screening proteins were then used to pan 
for high affinity anti -human ROR1 mAbs generated through the use of a proprietary enhanced 
phage library (Alere, Inc., San Diego, CA). High affinity antibodies that bind to the sam e epitope 
as D10 and more importantly exhibit the same anti -leukemic activity of this prototypical mAb were 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 13 of 59 identified. After cell line and animal testing and kinetic binding analysis, we chose a single 
antibody designated UC -99961 (UC -m961) for advancemen t in pre -clinical development.  
 
UC-m961 was humanized by BioAtla, Inc. (San Diego, CA). They employed a proprietary 
recombinant framework grafting technology to generate humanized antibodies that retain the 
biologic activities of the parent mAb. Over 20 d ifferent light and heavy chain humanized variant 
ROR1 targeting mAbs were screened.  
 
After conducting head -to-head analyses of several candidate humanized anti -ROR1 mAb, a final 
humanized mAb construct, designated UC -h961, was selected. This humanized mAb  is 
essentially humanized except for a few amino acids adjacent to the CDR borders and framework 
4, which for the most part are tucked under CDR3 in an immune protected site. UC -h961 will 
hereafter be referred to as UC -961 or Cirmtuzumab.  
 
1.2.1  Pre-Clinical Pharmacology and Toxicology  
To support the UC -961 phase I clinical trial, a comprehensive single -species 
pharmacology/toxicology study was conducted in rats.  In this study, groups of animals (15 of 
each sex) received UC -961 at doses of 40, 120 and 400 mg/ kg given weekly for 5 doses over 28 
days.  Three days following the final product administration, 20 animals (10 of each sex) in each 
dosing cohort were sacrificed and the remaining animals in the recovery phase sacrificed on day 
56.  During the study, par ameters measured included twice -daily clinical signs, food consumption, 
weekly body weights, ophthalmic examinations (pretreatment, after last dose and last week of 
drug-free period) urinalysis (prior to sacrifice) and clinical pathology indices including serum 
chemistries, hematology and coagulation studies (prior to sacrifice).  Safety pharmacology 
measurements including functional observation batteries were conducted weekly.  Finally, full 
necropsy and a complete microscopic analysis was performed on all  animals in all groups and a 
select panel of organs including the liver, spleen, heart, kidneys, brain and ovaries were weighed.   
 
In all dosing cohorts, the UC -961 drug product was well tolerated by the treated rats. No adverse 
events were noted during t he conduct of the study.  At terminal sacrifice gross pathologic exams 
were normal and no untoward effects of product administration were noted.   
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 14 of 59 1.2.2  Pre-Clinical Pharmacokinetics and Metabolism  
Comprehensive pharmacokinetic studies were conducted in both immune deficient mice  and in 
Wistar rats. Immune deficient mice  (Rag2 -/-c-/-) were injected i.v.  (1 mg/mouse), blood was 
drawn at different time points (left panel) and levels in plasma were measured by ELISA. One - 
compartment PK description of average data reveals that t1/2 = 11.4 days V= 1.18 mL (47 mL/kg) 
and CL = 0.072 mL/day (0.12 mL/hr/kg).  Fo r studies in rats, cohorts of animals received 400, 120 
and 40 mg/kg of UC -961 mAb and were screened at 14, 28, 42 and 56 days after treatment. The 
results (right panel) indicate that the UC -961 was removed from the rats with an apparent half -life 
of 7 day s irrespective of the initial dose of administered mAb.  
 
1.3 Rationale for Dose Selection  
The starting dose of 15 µg/kg is based upon international guidance for starting dose selection for 
agents in cancer patients (ICH S9 2010 Guidance for Industry) as well  as the guidance on 
biologics including monoclonal antibody therapies with minimal species cross -reactivity (Agoram, 
2009) .  Since UC -961 is specific for human ROR1 and the target epitope is only f ound in primates, 
there are no standard animal models that can be used for initial dose determination.  
 
Calculation of the initial UC -961 dose took into consideration the estimated average amount of 
UC-961 required to saturate the ROR1 surface molecules o n circulating CLL cells.  This 
calculated dose is based on the amount of mAb required to saturate the ROR1 surface molecules 
on the CLL cells in the blood multiplied by the number of leukemic cells in the blood.  
 
The amount of antibody required to saturat e the ROR1 surface molecules on CLL cells was 
determined using 2 -fold dilutions of the UC -961 antibody, which were used to bind CLL cells that 
subsequently were counter -stained with saturating amounts of fluorescein -conjugated anti -human 
antibody to detect  cell-bound UC -961 by flow cytometry.  We determined the amount of UC -961 
required to saturate binding of CLL cells. When the primary antibody is not saturating, the relative 
fluorescent signal is proportional to amount of antibody bound to the cells, whic h in turn is 
proportional to the number of ROR1 surface molecules.  We determined the amount of UC -961 
required to achieve 30% maximal binding to CLL cells.  We have analyzed primary CLL cells in 
this manner from more than 15 patients, and have extrapolate d these results to over 800 clinical 
samples based on mean fluorescent intensity (MFI) of CLL cells stained at saturation.  For a 
representative patient sample, approximately 3.3 ng of UC -961 was required to saturate the 30% 
of ROR1 surface molecules on 50 0,000 CLL cells, as assessed by flow cytometry.  
 
Along with the number of ROR1 surface molecules, the circulating CLL cell concentration may 
vary widely depending on the clinical parameters of the disease. CLL patients may have wide -
ranging numbers of cir culating CLL cells, from the thousands to over several hundred thousand.  

UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 15 of 59 To be inclusive and have a weight -based dosing regimen, we calculated the initial dose for a 
patient with a low body weight and a high circulating CLL count and high number of ROR1 -surface 
molecules.  Therefore, for a patient with an absolute lymphocyte count of 20,000/mm3, body 
weight of 50 kg, and circulating blood volume of 5L, the calculation for a first dose to saturate 30% 
of circulating ROR1 in such a patient is as follows:   
 
3.3 ng / 500,000 cells * 20,000 cells/mm3 * 1000mm3/ml * 5000 ml / 50kg = 13.2 µg/kg  
 
Therefore, we set the starting dose at 15 µg/kg (rounded up to account for variability of the 
ROR1 MFI between other CLL samples).    
  
Similarly, we calculated the dose t hat would occupy 60% of ROR1 on CLL cells in a typical patient. 
Based on preclinical data, 8.6 ng occupied 60% of ROR1 in 500,000 CLL cells. Based on 
calculation, the following dose saturates 60% of ROR1 in a patient with an absolute lymphocyte 
count of 20 ,000/mm3, body weight of 50 kg, and circulating blood volume of 5L:  
 
8.6 ng / 500,000 cells * 20,000 cells/mm3 * 1000mm3/ml * 5000 ml / 50kg = 34.4 µg/kg  
 
A two -fold increase in the rounded starting dose of 15 µg/kg would be 30 µg/kg, which is 
at or below  the amount required to achieve 60% saturation of ROR1 on CLL cells in the 
blood .  
 
Finally, although there is no species cross -reactivity, the starting dose is well below the NOEL for 
rodent studies for any non -specific activity. In the 28 -day rat study, the highest dose group was 
400 mg/kg for both males and females. No adverse events were noted, and no organ toxicity was 
noted on pathologic exams after terminal sacrifice. Therefore the STD 10 was not reached. The rat 
NOEL was therefore determined to be 40 0 mg/kg, which in theory would predict a human 
equivalent dose of 40 mg/kg. However, as the critical amino acids required for binding of the anti -
ROR1 mAb are only found in primates, the starting dose is also based on an estimate of the 
amount of antibody needed to saturate the ROR1 receptors on circulating CLL cells.  
 
1.4 Overview of Proposed Study  
UC-961 will be examined for safety and tolerability in patients with documented and verified 
relapsed or refractory CLL requiring treatment for their disease in a first in man, phase I physician -
sponsored clinical study.  The eligible patient population is appropriate for a phase 1 trial because 
of a lack of any standard treatment options that are capable of inducing complete or durable 
treatment -free responses. The  primary endpoint of the phase I trial will be to define the maximum 
tolerated dose (MTD) or biologically active dose of UC -961 administered as a single agent given 
on a bi -weekly (every two week) schedule for a total of four doses.  Secondary endpoints to  be 
measured include the assessment of clinical activity according to iwCLL working group criteria 
and progression free survival.  Additionally, pharmacokinetic parameters will be assessed and 
blood samples will be collected for correlative analysis. We an ticipate that 33 (but up to 56) 
patients will be enrolled..   
 
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 16 of 59 2.0 STUDY OBJECTIVES  
Primary Objective:   
1. To determine the maximum tolerated dose (MTD) or biologically active dose of UC -961 
when given bi -weekly for 4 doses to patients with relapsed or refractory chronic 
lymphocytic leukemia (CLL).  
Secondary Objectives:  
1. To determine the safety and tolerability of UC -961 by ongoing evaluation of adverse 
events (AEs).    
2. To assess clinical activity based on international working group guidelines (iwCLL 200 8). 
3. To assess clinical activity by evaluating progression free survival.  
Exploratory Objective:   
1. To assess the mechanism of action of UC -961 through immunophenotypic, genomic, 
proteomic, and pharmacodynamic studies.  
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 17 of 59 3.0 PATIENT ELIGIBILITY  
3.1 Inclusion Criteria  
Subjects  must meet all of the inclusion criteria to participate in this study.  
 
1. Ability to understand and the willingness to sign a written informed consent.  
 
2. Clinical and phenotypic verification of B cell CLL and measurable disease. 
Immunophenotyping of the leukemic cells (blood or marrow) must demonstrate a 
monoclonal (or light chain positive) with immunophenotype consistent with B cell 
population (e.g., co -expressing CD19 and CD5).  
 
3. Relapsed or refractory disease, defined by failure to achieve a partial  response within 
6 months of initiation of first line therapy, or a 50% worsening  of baseline disease 
measurements  (i.e., lymph node size, splenomegaly, lymphocytosis, anemia, 
thrombocytopenia, hepatomegaly)   after achieving a clinical response.  
 
4. Not amen able to approved therapies.  
. 
5. Prior Therapy: Must have progressed after purine -analog or alkylator based therapy, 
or be considered inappropriate for chemo -immunotherapy due to one of the following:  
 Del 17p, which is associated with poor response to chemo -immunotherapy, or  
 Age greater than 70, or  
 Age greater than 65 with one of the following:  
o Grade  3 neutropenia, anemia, or thrombocytopenia attributable to 
cumulative myelotoxicity from prior administration of cytotoxic agents 
(as documented by bone marrow biopsy obtained since last prior 
therapy), or  
o Clinically apparent autoimmune cytopenia, which m ay be exacerbated 
by fludarabine therapy, or  
o Estimated creatinine clearance (eC Cr) <70 mL/min (as determined by 
the Cockcroft -Gault method), or  
o ECOG performance status greater than 0.  
 
6. Has recovered from the toxic effects of prior therapy to their clinical  baseline.  
 
7. Subjects must be aged 18 years or older.  
 
8. Both men and women of all races and ethnic groups are eligible for this trial.  
 
9. Women of childbearing potential (not postmenopausal for at least one year or not 
surgically incapable of bearing children ) must agree not to become pregnant for the 
duration of the study. Both men and women must agree to use a barrier method of 
contraception for the duration of the study and until 10 weeks after the final dose of 
UC-961 (expected to be greater than 5 half -lives from pre -clinical data).  
 
10. Subjects must have at least one of the following indications for treatment:  
 Symptomatic or progressive splenomegaly;  
 Symptomatic lymph nodes, nodal clusters, or progressive lymphadenopathy;  
 Progressive anemia (hemoglobin ≤ 11 g/dL);  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 18 of 59  Progressive thrombocytopenia (platelets ≤ 100 x 109/L);  
 Weight loss > 10% body weight over the preceding 6 month period;  
 Fatigue attributable to CLL;  
 Fever or night sweats for > 2 weeks without evidence of infection;  
 Progressive lymphocytosis with an increase of > 50% over a 2 -month period 
or an anticipated doubling time of less than 12 months.  
 
11. Subjects must have an ECOG performance status of 0 -2.  
 
12. Adequate hematologic function:   
 Platelet count  50,000/µL unless du e to heavily infiltrated bone marrow (> 
80% CLL cell infiltrate); AND  
 Hemoglobin  8.0 g/dL (may be supported by erythropoietin); AND  
 Absolute neutrophil count > 1000 /uL unless due to heavily infiltrated bone 
marrow (> 80% CLL cell infiltrate).  
 
13. Adequate renal function:  
 Serum creatinine <1.5 times upper limit of normal; OR  
 Calculated Creatinine clearance (CrCl) ≥ 40 mL/min (based upon the 
Cockcroft -Gault Equation [CrCl = (140 -age) * actual wt (in kg) * (0.85 if female) 
/ (72 * Cr)].  
 
14. Adequate hepatic funct ion: 
 Total bilirubin ≤ 2.5 times upper limit of normal; AND  
 ALT ≤ 2.5 times upper limit of normal.  
 
15. Adequate coagulation tests:  
 Prothrombin time international normalized ratio (INR) ≤ 2; AND  
 Partial thromboplastin time ≤ 1.66 times upper limit of normal.  
3.2 Exclusion Criteria  
Subjects meeting any of the exclusion criteria at baseline will be excluded from study participation.  
 
1. Pregnant or breast -feeding women will not be entered on this study due to risks of fetal 
and teratogenic adverse events as seen in ani mal/human studies. IgG may cross the 
placental barrier and cause fetal B - and T -lymphocyte depletion. Therefore, women of 
child-bearing age must obtain a pregnancy test and pregnant or breast feeding 
females are excluded.  
 
2. Patients who are currently recei ving another investigational agent are excluded.  
 
3. Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), 
immunotherapy, radiation therapy, or participation in any investigational drug 
treatment within 4 weeks of initiation of UC-961, or at any time during the study.  
 
4. Patients who have had prior (within 8 weeks of initiation of UC -961) or concurrent 
antibody therapy directed against CLL (i.e., Rituxan® and Campath ®) 
 
5. Current infection requiring parenteral antibiotics.  
 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 19 of 59 6. Active infection with HIV, HBV, or HCV.  
 
7. Concurrent active malignancy or prior malignancy that was active within the previous 
3 years (other than completely resected carcinoma in situ, prostate cancer, or localized 
non-melanoma skin cancer).  
 
8. Known centr al nervous system (CNS) involvement by malignancy.  
 
9. Untreated autoimmunity such as autoimmune hemolytic anemia, or immune 
thrombocytopenia.  
 
10. Known u ncompensated hypothyroidism (defined as greater than 2x upper limit of 
normal not treated with replacement hormone).  
 
11. Presence of more than 55% pro -lymphocytes in peripheral blood. Patients with 
Richters transformation are not excluded.  
 
12. Insufficient recovery from surgical -related trauma or wound healing.  
 
13. Impaired cardiac function including any of the followi ng: 
 Myocardial infarction within 6 months of starting study drug;  
 A past medical history of clinically significant ECG abnormalities, including 
QTc 481 ms or greater.  
 Other clinically significant heart disease (e.g. congestive heart failure, 
uncontrolled hypertension, history of labile hypertension, or history of poor 
compliance with an antihypertensive regimen)  
 
14. Patients who in the opinion of the investigator may be unable to comply with the safety 
monitoring requirements of the study.  
 
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 20 of 59  
4.0 INVESTIGATIONAL  TREATMENT PLAN  
4.1 Dose Assignment  
This is a first in human, open -label single institution, Phase I dose escalation study of in patients 
with relapsed or refractory CLL.  Treatment cycle (14 days) will consist of UC-961 administered 
intravenously on a bi -week ly (every two weeks) schedule for a total of 4 doses. Twelve dose levels 
are planned (in 8 cohorts) with dose escalation described in Table 1.  Seven  dose cohorts (of 3 to 
6 patients in size) plus an expansion cohort of 6 patients are planned. In the first 4 dose cohorts, 
there is intra -patient dose escalation to monitor for acute toxicities, such as tumor lysis syndrome. 
If any grade ≥ 2 adverse  event occurs in the cohort with intra -patient dose escalation, then the 
dose -escalation scheme will switch to sta ndard 3+3 dose -escalation design without intra -patient 
dose escalation . All adverse events should be considered relevant unless the event can clearly 
be determined to be unrelated to the drug, e.g., clearly related to disease progression.  
 
Table 1. Dose escalation scheme  
 Dose Cohort  Dose of UC -961  
Starting Dose  
Intra-patient dose 
escalation  
 1 Cycle 1 = 15 µg/kg  
Cycle 2 = 15 µg/kg  
Cycle 3 = 30 µg/kg  
Cycle 4 = 30 µg/kg  
Intra-patient dose 
escalation  
 2 Cycle 1 = 60 µg/kg  
Cycle 2  = 120 µg/kg  
Cycle 3 = 240 µg/kg  
Cycle 4 = 240 µg/kg  
Intra-patient dose 
escalation  
 3 Cycle 1 = 500 µg/kg  
Cycle 2 = 1000 µg/kg  
Cycle 3 = 1000 µg/kg  
Cycle 4 = 1000 µg/kg  
Intra-patient dose 
escalation  4 Cycle 1 = 2 mg/kg  
Cycle 2 = 2 mg/kg  
Cycle 3 = 4 mg/kg  
Cycle 4 = 4 mg/kg  
 5 8 mg/kg  
 
 6 16 mg/kg (or maximum 2000mg)  
 7 20 mg/kg (or maximum 2000mg)  
 
Dose escalation  will be performed in serial patient cohorts. Up to six patients can be studied at 
each dose level. There will be a minimum interval of 48 hours or more between the initiation of 
therapy for new patients within each cohort. Safety and clinical data will be  tabulated and the 
decision to open the next cohort level will be the responsibility of the principal investigator. Dose 
escalation will be based on the dose -limiting toxicities encountered during the dose -limiting 
toxicity (DLT) evaluation period (see 4.2  for DLT definitions).  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 21 of 59  If none of the 3 patients in the dosing cohort experience a DLT, then dose escalation may 
proceed.  
 If 1 of the 3 patients experiences a DLT, then the cohort will be expanded to 6 patients.  If 
none of these additional patients exper ience a DLT, then dose escalation will continue.  
 If 2 patients in the dose level experience a DLT, no further escalation will occur.  The MTD 
will be defined as 1 dose level lower than the dose level at which at least 2 of 6 patients 
experienced a DLT.  
 Successive dose reductions of 50% from the dose proposed in the initial cohort (2 mg/kg) 
will be used until a tolerated dose is identified, if DLTs are seen in 2 or more patients in 
the initial cohort.  
 The Maximum Tolerated Dose (MTD)  is defined as the hig hest dose studied at which no 
more than 1 in 6 patients experience a DLT in the DLT observation period.  
 
DLT observation period  is 56 days from the start of the first infusion  for cohorts with intra -patient 
dose escalation ; and 28 days after the start of t he first infusion of UC -961 for subsequent cohorts. 
The subsequent cohort will not be enrolled until this DLT observation period has been completed 
for all patients in the prior dose cohort.  
 
Replacement patients  may be enrolled in a cohort for patients wh o withdraw for a reason that is 
definitely unrelated to toxicity of UC -961 (e.g. disease progression). Replacement patients will 
ensure enough patients are enrolled in each cohort to determine the MTD.  
 
The Biologically Active Dose  will be determined at a dose below or equal to the MTD upon review 
of study data by the investigators. The final determination will also take into account any 
cumulative or delayed toxicity (e.g., an adverse event that occurs later than the DLT observation 
period).  
 
Expansion coh ort: Six additional patients will be enrolled at the maximum tolerated dose or 
biologically active dose.  
4.2 Dose Limiting Toxicity  
Dose -Limiting Toxicity (DLT) is defined as any of the following adverse events that are 
considered by the investigator to be pos sibly, probably, or definitely related to the study agent 
UC-961 within the DLT observation period (56 days from the first infusion for cohorts with 
intrapatient dose escalation, and 28 days of the start investigational treatment  for cohorts without 
intrap atient dose escalation):  
a. Grade 3 or greater non -hematologic toxicity with the exceptio n of Grade 3 infusion 
reaction.  
b. Grade 4 neutropenia lasting more than 5 days  despite appropriate medical 
management . 
c. Grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding or any 
requirement for platelets transfusion.  
d. Grade 3 or greater febrile neutropenia (temperature ≥ 38.5ºC).  
e. Grade 4 anemia unexplained by underlying disease.  
f. Any AE requiring a dose delay of greater than 14 days.  
g. Patients with baseline cytopenias or starting blood counts in the grade 2 range are 
evaluable for hematologic DLT.  
 
All AEs occurring in the first two cycles should be considered relevant to determining DLTs and 
to reporting unless the event can clearly be determined to be unrelated to the study drug.  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 22 of 59  
4.3 Recommended Pre -Medications and Concomitant Medications  
 
1. Antibiotic s: per investigator discretion.  
 
2. Tumor lysis syndrome prophylaxis:  Patients will receive allopurinol or another uric 
acid lowering agent. Blood samples will be drawn upon completion of the infusion and 
24 hours (+/ - 4 hours) later to perform a comprehensi ve metabolic panel and to test 
serum levels of uric acid, phosphorous, and calcium.  Management of tumor lysis 
syndrome is described in section 4.6.3.  
 
3. Infusion reaction prophylaxis:  
 
 Acetaminophen 325 -1000 mg PO prior to UC -961 administration, or per 
investigator discretion.  
 Benadryl 50 mg IV or PO, or other antihistamine per investigator discretion, prior 
to UC -961 administration.  
 Optional: Hydrocortisone 100 mg IV bolus (or infusion over 30 +/ -10 minutes) or 
other equivalent corticosteroid, prior to U C-961 infusion.  
 
4.4 UC-961 infusion plan  
 
FOR COHORT 1 (i .e., DOSES ≤ 30 µg/kg)  
Initial Infusion (Cycle 1, Day 1, FOR COHORT 1)  
 Test dose:  Infuse 100 µg/hour for 10 minutes, then stop infusion (or sooner if not 
tolerated prior to 10 minutes). 10 minutes (+/ -5 minutes) following completion of 
test dose, monitor for any signs or symptoms of infusion reaction, including: 
hypotension (greater than 30 mm H g drop in systolic blood pressure from 
baseline); fever (temperature greater than 101.3 degrees Fahrenheit); rigors . 
Management / supportive measures for these events is per institutional standards.  
 In the absence of any of vital sign instability or signs/ symptoms of infusion 
reaction, or after normalization of them,  begin infusion:  
 Initiate infusion at 100 µg/hr x 30 min (+/ - 5 minutes)  
 Check vital signs every 30 minutes (+/ - 5 minutes).  
 If vital signs are stable (SBP is within 20 mm Hg of baseline, HR > 60 or < 120 
beats per minute or within 10% of baseline, and temperature <101.3 F) and without 
sign/symptoms of infusional toxicity, the rate of infusion is doubled every 30 
minutes (+/ - 5 minutes) to a maximum of 800 µg/hr for remainder of infusion.  
 If a p atient is unable to tolerate faster rate, continue infusion at the best tolerated 
rate until infusion is completed. Monitor for acute infusion -related reactions during 
and for 30 minutes (+/ - 5 minutes) after infusion completed.  
 Hold infusion and immediate ly notify MD if any of the following occur: hypotension 
(greater than 30 mm Hg drop in systolic blood pressure from baseline); fever 
(temperature greater than 101.3 degrees Fahrenheit); rigors. Management / 
supportive measures for these events is per insti tutional standards. Infusion of UC -
961 is resumed at half the previous rate once vital signs and symptoms have 
returned to baseline.  
Subsequent Infusions (Day 1 of Cycles 2 -4, FOR COHORT 1)  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 23 of 59  Test dose is not required.  
 Initiate infusion at rate of 200 µg/hr (or at highest previously tolerated rate if it is 
lower than 200 µg/hr).  Maximum infusion rate is 1600 µg/hr. Remainder of 
infusion, vital sign monitoring, and management of infusion reaction as above.  
 
FOR COHORT 2 (or doses 60 µg/kg to 240 µg/kg):  
Initial Infusion (Cycle 1, Day 1, FOR COHORT 2)  
 Test dose:  Infuse 400 µg/hour for 10 minutes, then stop infusion (or sooner if not 
tolerated prior to 10 minutes). 10 minutes (+/ -5 minutes) following completion of 
test dose, monitor for any signs or symptom s of infusion reaction, including: 
hypotension (greater than 30 mm Hg drop in systolic blood pressure from 
baseline); fever (temperature greater than 101.3 degrees Fahrenheit); rigors . 
Management / supportive measures for these events is per institutional standards.  
 In the absence of any of vital sign instability or signs/symptoms of infusion 
reaction, or after normalization of them,  begin infusion:  
 Initiate infusion at 400 µg/hr x 30 min (+/ - 5 minutes)  
 Check vital signs every 30 minutes (+/ - 5 minutes).  
 If vital signs are stable (SBP is within 20 mm Hg of baseline, HR > 60 or < 120 
beats per minute or within 10% of baseline, and temperature <101.3 F) and without 
sign/symptoms of infusional toxicity, the rate of infusion is doubled every 30 
minutes (+/ - 5 minutes) to a maximum of 3200 µg/hr for remainder of infusion.  
 If a patient is unable to tolerate faster rate, continue infusion at the best tolerated 
rate until infusion is completed. Monitor for acute infusion -related reactions during 
and for 30 minutes (+/- 5 minutes) after infusion completed.  
 Hold infusion and immediately notify MD if any of the following occur: hypotension 
(greater than 30 mm Hg drop in systolic blood pressure from baseline); fever 
(temperature greater than 101.3 degrees Fahrenheit); r igors. Management / 
supportive measures for these events is per institutional standards. Infusion of UC -
961 is resumed at half the previous rate once vital signs and symptoms have 
returned to baseline.  
Subsequent Infusions (Day 1 of Cycles 2 -4, FOR COHORT 2) 
 Test dose is not required.  
 Initiate infusion at rate of 1600 µg/hr (or at highest previously tolerated rate if it is 
lower than 1600 µg/hr).  Maximum infusion rate is 6400 µg/hr . Remainder of 
infusion, vital sign monitoring, and management of infusion re action as above.  
 
FOR COHORT 3 (doses 500 µg /kg to 1000 µg /kg) 
Initial Infusion (Cycle 1, Day 1, cohorts 3)  
 Test Dose:  Infuse 2 mg/hour for 10 minutes, then stop infusion (or sooner if not 
tolerated prior to 10 minutes). 10 minutes (+/ -5 minutes) followin g completion of 
test dose, monitor for any signs or symptoms of infusion reaction, including: 
hypotension (greater than 30 mm Hg drop in systolic blood pressure from 
baseline); fever (temperature greater than 101.3 degrees Fahrenheit); rigors . 
Management /  supportive measures for these events is per institutional standards.  
 In the absence of any of vital sign instability or signs/symptoms of infusion 
reaction, or after normalization of them,  begin infusion:  
 Initiate infusion at 2 mg/hr x 30 min (+/ - 5 minut es) 
 Check vital signs every 30 minutes (+/ - 5 minutes).  
 If vital signs are stable (SBP is within 20 mm Hg of baseline, HR > 60 or < 120 
beats per minute or within 10% of baseline, and temperature <101.3 F) and without 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 24 of 59 sign/symptoms of infusional toxicity,  the rate of infusion is doubled every 30 
minutes (+/ - 5 minutes) to a maximum of 24 mg/hr for remainder of infusion.  
 If a patient is unable to tolerate faster rate, continue infusion at the best tolerated 
rate until infusion is completed. Monitor for acut e infusion -related reactions during 
and for 30 minutes (+/ - 5 minutes) after infusion completed.  
 Hold infusion and immediately notify MD if any of the following occur: hypotension 
(greater than 30 mm Hg drop in systolic blood pressure from baseline); fever  
(temperature greater than 101.3 degrees Fahrenheit); rigors. Management / 
supportive measures for these events is per institutional standards. Infusion of UC -
961 is resumed at half the previous rate once vital signs and symptoms have 
returned to baseline.  
Subsequent Infusions (Day 1 of Cycles 2 -4, cohorts 3)  
 Test dose is not required.  
 Initiate infusion at rate of 8 mg/hr (or at highest previously tolerated rate if it is 
lower than 8 mg/hr). Maximum infusion rate is 48 mg/hr. Remainder of infusion, 
vital sign monitoring, and management of infusion reaction as above.  
 
FOR COHORT 4 -8 (doses 2mg/kg and higher)  
Initial Infusion (Cycle 1, Day 1, cohorts 4 -8) 
 Test Dose:  Infuse 25 mg/hour for 10 minutes, then stop infusion (or sooner  if not 
tolerated prior to 10 minutes). 10 minutes (+/ -5 minutes) following completion of 
test dose, monitor for any signs or symptoms of infusion reaction, including: 
hypotension (greater than 30 mm Hg drop in systolic blood pressure from 
baseline); fever  (temperature greater than 101.3 degrees Fahrenheit); rigors . 
Management / supportive measures for these events is per institutional standards.  
 In the absence of any of vital sign instability or signs/symptoms of infusion 
reaction, or after normalization o f them,  begin infusion:  
 Initiate infusion at 25 mg/hr x 30 min (+/ - 5 minutes)  
 Check vital signs every 30 minutes (+/ - 5 minutes).  
 If vital signs are stable (SBP is within 20 mm Hg of baseline, HR > 60 or < 120 
beats per minute or within 10% of baseline, and temperature <101.3 F) and without 
sign/symptoms of infusional toxicity, the rate of infusion is doubled every 30 
minutes (+/ - 5 minutes) to a maximum of 800 mg/hr for remainder of infusion.  
 If a patient is unable to tolerate faster rate, continue infus ion at the best tolerated 
rate until infusion is completed. Monitor for acute infusion -related reactions during 
and for 30 minutes (+/ - 5 minutes) after infusion completed.  
 Hold infusion and immediately notify MD if any of the following occur: hypotension 
(greater than 30 mm Hg drop in systolic blood pressure from baseline); fever 
(temperature greater than 101.3 degrees Fahrenheit); rigors. Management / 
supportive measures for these events is per institutional standards. Infusion of UC -
961 is resumed at hal f the previous rate once vital signs and symptoms have 
returned to baseline.  
  
Subsequent Infusions (Day 1 of Cycles 2 -4, cohorts 4 -8)  
 Test dose is not required.  
 Initiate infusion at rate of 50 mg/hr  (or at highest previously tolerated rate if it is 
lower than 50 mg/hr). Maximum infusion rate is 800 mg/hr. Remainder of 
infusion, vital sign monitoring, and management of infusion reaction as above.  
 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 25 of 59 4.5 Criteria for Starting Subsequent Cycles  
A cycle may be repeated every 14 days if the patient has at least stable disease by clinical 
examination (or interim response assessment) and has again met hematologic, renal, and hepatic 
laboratory parameters as defined in the eligibility section, and is without ongoing Grade 3 non -
hematologic or Grade 4 hematologic toxicities attributable to UC -961.  
 
4.6 Dose Modifications and Dosing Delays  
Each patient will be assessed for the development of toxicity according to the NCI Common 
Toxicity Criteria for Adverse  Events (CTCAE), version 4.03 for non -hematologic toxicity or 
modified iwCLL criteria  (section 7.1.2) for hematologic toxicity. Patients experiencing a DLT as 
defined in section 4.2 will be discontinued from study treatment. Otherwise, dose adjustments 
should be made according to the system showing the greatest degree of toxicity, as per 4.6.1, 
unless the adverse event is definitely unrelated to the study drug.  
  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 26 of 59  
4.6.1  Dose Modification Guidelines  
Toxicity – NCI CTCAE Grade  
(Hematologic - modified 
iwCLL)  Occurre nce Dose Modification  
Autoimmune anemia or autoimmune thrombocytopenia  
Grade ≥ 2  any Withhold study treatment until resolved to 
Grade ≤ 1.  
 
Resume study treatment at same dose level.  
Tumor Lysis Syndrome  
Grade ≥ 3  1st Withhold study treatment until clinical and 
laboratory signs resolved to baseline.  
 
Resume study treatment at same dose level.  
 Repeat  Discontinue therapy  
Confusion / Delirium  
Grade ≥ 2  1st Withhold study treatment until resolved to 
Grade ≤ 1.  
 
Resume study treatment at the next lower 
dose level.  
Repeat  Discontinue therapy  
Pneumonitis  
Grade ≥ 2  1st Withhold study treatment until resolved to 
Grade ≤ 1.  
 
Resume study treatment at the next lower 
dose level.  
Repeat  Discontinue therapy  
Acute kidney injury  
Grade ≥ 2 (serum creatinine > 
2 x baseline)  1st Withhold study treatment until resolved to 
Grade ≤ 1.  
 
Resume study treatment at the next lower 
dose level.  
Repeat  Discontinue therapy  
Cardiac - QTc 
ECGs with a QTc 481 -500 msec 
(Grade 2)  1st Suspend study treatment and perform an analysis 
of serum potassium and magnesium, and if below 
lower limit of normal, correct with supplements to 
within normal limits. Concomitant medication 
usage must be reviewed.  
 
Perform a repeat ECG within one hour of the first 
QTc of > 480 msec.  If QTc remains >480 msec, 
repeat ECG as clinically indicated until the QTc 
returns to <480 msec.  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 27 of 59 - Study treatment may be restarted at the current 
dose level, if the reason for the QTc elevation is 
identified, corrected and QTc returns to 
baseline (pre -dose  Cycle 1 day 1) within 7 days.  
- If QTc is repeated and is greater than baseline, 
reduce study treatment to the lower dose level.  
- An ECG should be repeated approximately 7 
days after dose re -start for all patients who had 
therapy suspended due to QTcF > 480 msec.  
- If QTc remains >480 msec for greater than 7 
days, discontinue treatment.  
 Repeat  Discontinue study treatment.  
ECGs with a QTc ≥ 501 msec 
(Grade 3)  1st Discontinue study treatment.  
ECGs with QTc ≥  501 or > 60 
ms change from baseline and 
Torsade de pointes or 
polymorphic ventricular 
tachycardia or  
signs/symptoms  
(Grade 4)  1st Discontinue study treatment.  
Other Non -hematologic  
Grade ≥ 3  1st Withhold study treatment until resolved to 
Grade ≤ 2.  
 
Resume study treatment at the next lower 
dose level.  
Repeat  Discontinue therapy.  
Hematologic*  
ANC <1000/mm3; 
Hemoglobin < 8 gm/dL;  
Platelet count ≥ 50% decrease 
from baseline (and/or platelet 
count ≤ 50,000/mm3) 1st Withhold study treatment until resolved to 
ANC ≥1000/mm3, hemoglobin is ≥ 8 gm/dL, 
and platelet count ≥50,000/mm3.  
Resume study treatment at same dose.  
2nd Withhold study treatment until resolved to 
ANC ≥1000/mm3, hemoglobin is ≥ 8 gm/dL,  
and platelet count ≥50,000/mm3.  
Resume study treatment at t he next lower 
dose level.  
3rd Permanently discontinue study treatment.  
*Dose adjustments or dose holds for hematologic toxicity will apply even if the baseline values 
are lower than these thresholds due to heavily infiltrated marrow. In those cases, growth factors 
and/or blood product transfusion may be administered prior to continuing with UC -961. 
Notes:   
1. If any of the above are noted, the patient will be re -assessed within 7 days by the treating 
physician or investigator. Isolated laboratory abnormalities may be re -evaluated by 
laboratory draw only, or based on physician or investigator discretion.  
2. UC-961 infusions can be delayed for a maximum of 28 days; if not restarted in that time -
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 28 of 59 span, study treatment will be permanently discontinued.  
3. If dose is decreased for Grade 3 or 4 toxicity, dose re -escalation is not planned.  
4. For invasive procedures, not including biopsies or venous catheter placement: withhold 
study treatment for 1 week prior to procedure, and at least 1 week following surgery unti l 
satisfactory wound healing has been achieved.  
 
4.6.2  Modifications for Infusion Reactions  
Patients will be monitored for the presence of infusion -related reactions. Treatment for infusion -
related reactions will be managed according to the following guidelines:  
Infusion Reaction  Occurrence  Management Guidelines  
Grade ≤ 2  any Institute supportive measures.  
 
When resolved, resume study treatment at same 
dose level. Infusion rate adjustment per 4.4.  
Grade 3  
 1st Institute supportive measures.  
 
When resolved, resume study treatment at the same 
dose level. Infusion rate adjustment per 4.4. Pre -
medications listed in protocol are mandatory for re -
challenge.  
2nd Institute supportive measures.  
 
Permanently discontinue study treatment.  
Grade 4  any Institute institutional procedures for adult medication 
reaction/anaphylactic response.  
Permanently discontinue study treatment.  
 
4.6.3  Management of tumor lysis syndrome  
 
Event  Management Guidelines  
Hyperkalemia  
Potassium ≥ 0.5 
mmol/L increase 
from prior value 
(even if potassium is 
within normal limits 
[WNL])  - Recheck K+, Phos, uric acid, calcium & creatinine in 1 hour STAT.  
- If further ≥ 0.2 mmol/L increase in K+, but still < ULN, manage as 
per K+ ≥ ULN. Otherwise recheck in 1 hour.  
- If change in K+is < 0.2 mmol/L 1 ho ur later, and K+ < ULN,  and 
no other evidence of tumor lysis, resume per protocol monitoring.  
Potassium > ULN  - Perform STAT EKG  
- Administer Kayexalate 60 g  
- administer furosemide 20 mg IV x 1  
- Administer calcium gluconate 100 to 200 mg/kg IV slowly if there 
is EKG evidence of arrhythmia  
- Recheck K+, Phos, uric acid, calcium, and creatinine in 1 hour 
STAT  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 29 of 59 Event  Management Guidelines  
- If L+ < ULN 1 hour later, repeat K+, Phos, uric acid, calcium, and 
creatinine 1, 2, and 4 hours, if no other evidence of tumor lysis 
syndrome  
- At discretion of  investigator, admission to hospital, and nephrology 
consultation for consideration of initiating dialysis.  
- Admission required for any increase ≥ 1 mmol/L  
Potassium ≥ 6.0 
mmol/L (6.0 mEq/L) 
and/or symptomatic 
(e.g. muscle cramps, 
weakness, 
paresthesias, 
nausea, vomiting, 
diarrhea)  - Perform STAT EKG  
- Administer Kayexalate 60 g  
- Administer furosemide 20 mg IV x 1  
- Administer insulin 0.1 U/kg IV + D25 2 ml/kg IV  
- Administer sodium bicarbonate 1 to 2 mEq IV push.  
- If sodium bicarbonate is used, rasburicase  should not be used as 
this may exacerbate calcium phosphate precipitation.  
- Administer calcium gluconate 100 to 200 mg/kg IV slowly if there 
is EKG evidence of arrhythmia  
- Recheck K+, Phos, uric acid, calcium, and creatinine in 1 hour 
STAT  
- If L+ < ULN 1 hour later, repeat K+, Phos, uric acid, calcium, and 
creatinine 1, 2, and 4 hours, if no other evidence of tumor lysis 
syndrome  
- Admission to hospital, and nephrology consultation for 
consideration of initiating dialysis, unless all repeat lab s are WNL.  
 
Hyperuricemia  
Uric acid ≥ 8.0 mg/dL  - Consider rasburicase (dose per institutional guidelines)  
- Recheck K+, Phos, uric acid, calcium, and creatinine in 1 hour 
STAT  
 
Uric acid ≥ 10 mg/dL 
OR uric acid ≥ 8.0 
mg/dL  with 25% 
increase and 
Creatinine increase ≥ 
0.3 mg/dL from pre -
dose level  - Administer rasburicase (dose per institutional guidelines)  
- Recheck K+, Phos, uric acid, calcium, and creatinine in 1 hour 
STAT  
- If uric acid < 8.0 mg/dL 1 hour later, repeat K+, Phos , uric acid, 
calcium, and creatinine 2 and 4 hours later, if no other evidence of 
tumor lysis.  
- Admission to hospital, and nephrology consultation for 
consideration of initiating dialysis, unless all repeat labs are WNL.  
-  
 
Calcium ≤ 7.0 mg/dL 
AND patient 
symptomatic (e.g. 
muscle cramps, 
hypotension, tetany, 
arrhythmias)  - Administer calcium gluconate 50 to 100 mg/kg IV slowly with ECG 
monitoring.  
- Recheck K+, Phos, uric acid, calcium, and creatinine in 1 hour 
STAT  
- If Ca normalized 1 hour later, repeat K+, Phos , uric acid, calcium, 
and creatinine 2 and 4 hours later, if no other evidence of tumor 
lysis.  
- Calculate corrected calcium and check ionized calcium if albumin 
low. 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 30 of 59 Event  Management Guidelines  
Phosphorous ≥ 5.0 
with ≥ 0.5 mg/dL 
increase  - Administer phosphorous binder  
- Recheck K+, Phos , uric acid, calcium, and creatinine in 1 hour 
STAT  
- Admission to hospital and nephrology consultation (dialysis 
required for phosphorous ≥ 10 mg/dL  
- If Phos < 5.0 mg/dL 1 hour later, repeat K+, Phos, uric acid, 
calcium, and creatinine 2 and 4 hours later, i f no other evidence of 
tumor lysis.  
Creatinine ≥ 25% 
from baseline  - Administer IV fluids at 100 to 200 ml/hr for 4 hours  
- Recheck K+, Phos, uric acid, calcium, and creatinine in 1 -2 hours 
STAT  
- Admission to hospital and nephrology consultation if creatinine 
increase by ≥ 10% on repeat check.  
- If not admitted, ensure oral hydration of at least 3 L/ day.  
 
4.7 Permitted concomitant therapy  
 
Supportive Care  
Appropriate antibiotics, anti -emetics, fluids, electrolytes and general supportive care are to be used 
as necessary.  
 
Blood Products and Growth Factors  
Blood products or myeloid growth factors can be administered for grade 4 toxicities (DLT), per 
investigator discretion for patient safety. The Principal Investigator (C. Jamieson, MD PhD of M. 
Choi, MD) should be called before growth factors are initiated. Erythropoietin or thrombopoietin 
mimetics are not to be used, unless continuation of a therapy that started ≥ 1 day prior to Cycle 
1, Day 1.  
 
4.8 Prohibited concomitant therapy  
 
Concurrent Anticancer Therapy  
Concurrent cancer therapy, including chemotherapy, radiation therapy, immunotherapy, or 
biologic therapy may NOT be administered to patients receiving study drug. Corticosteroids 
administration, even if for treatment of conditions other than CLL, at doses greater than 
prednisone 20 mg daily (or equivalent dose of other steroids) are prohibited for greater than 14 
days. If these treatments are administered the patient will be removed from study.  
 
Investigational Agents  
No other investigational agents may be given while the patient is on study.  
 
4.9 Duration of Therapy  
The investigational agent UC -961 will be administered every two weeks for four doses or until:   
a) Clinical or radiographic progressive disease.  
b) Unacceptable toxicities.  
c) Refusal of further protocol the rapy by patient.  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 31 of 59 d) Non-compliance that in the opinion of the investigator does not allow for ongoing 
participation.  
e) Completion of therapy.  
f) Physician determines it is in the patient’s best interest to discontinue study agent.  
 
Clinical Study Stopping Rules: Enrollment will be held pending review and approval by the UC 
San Diego Moores Cancer Center Data Safety Monitoring Board (DSMB) in the event of either of 
the following:  
 Death, or  
 2 or more non -hematologic Grade 4 events at least possibly attributable to the study drug 
not resolving with standard therapy within 7 days. Grade 4 hematologic events will not 
stop the study, but do meet protocol -defined criteria for Dose Limiting Toxicity.  
4.10 Duration of Follow Up  
Patients removed from study treatment  for unaccept able adverse events will be followed until 
resolution or stabilization of the adverse event. Patients will be followed after removal from study 
treatment every 28 days (+/ -7 days) for 8 visits, then every 56 days (+/ - 7 days) until death, lost 
to follow -up, withdrawal of consent, or initiation of subsequent therapy for disease progression 
(see Section 5 for assessments ).  
 
4.11 Criteria for Removal from Study  
Patients can be taken off the study at any time at their own request, or they may be withdrawn at 
the di scretion of the investigator for safety, behavioral or administrative reasons. The reason(s) 
for discontinuation will be documented and may include:  
a) Death.  
b) Loss to follow -up. 
c) Withdrawal of consent for any further data submission.  
d) Disease progression requir ing initiation of subsequent therapy.  
e) Administration of any c oncurrent cancer therapy (including chemotherapy, 
radiation therapy, immunotherapy, or biologic therapy).  
f) Administration of corticosteroids at doses greater than prednisone 20 mg daily (or 
equiva lent dose of other steroids) for greater than 14 days.  
 
5.0 STUDY PROCEDURES  
 
A cycle is considered to be 14 days. The total duration of study drug administration is 4 cycles. 
Each cycle consists of clinical and laboratory evaluation on Day 1 (+/ - 1 day), and safety 
assessments on Days 3 and 8.  
 
5.1 Screening/Baseline Procedures  
Assess ments performed exclusively to determine eligibility for this study will be done only after 
obtaining informed consent. Assessments performed for clinical indications (not exclusively to 
determine study eligibility) may be used for baseline values even if the studies were done before 
informed consent was obtained.  
 
All screening procedures must be performed within 30 days prior to Cycle 1 Day 1 of the study 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 32 of 59 unless otherwise stated. The screening procedures include:  
5.1.1  Complete history and physical examination including vital signs (blood pressure, heart 
rate, temperature, weight) and organ measurements (i.e., lymph nodes, spleen, liver).  
5.1.2  Current medications will be recorded in the subject's medical record but not captured in 
case report forms.  
5.1.3  12 lead ECG. ECG  is required on screening. Subsequent ECG will be performed during 
the study as clinically indicated.  
5.1.4  Laboratory examinations: hematology (CBC w/differential), comprehensive metabolic 
panel (Na+, Cl -, K+, CO2, BUN, Creatinine, Glucose, Ca2+, total protein , albumin, total 
bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium, uric acid, 
LDH, amylase, lipase.  
5.1.5  Coagulation parameters: PT/PTT.  
5.1.6  Serum β2-microglobulin, T -cell subsets, and quantitative immunoglobulins (IgG, IgA, 
IgM).   
5.1.7  Infectious  disease screening unless known within 56 days, including: HBsAG, anti -HBs, 
total anti -HBc, IgM anti -HBc), Hep C virus antibody + RNA if antibody positive, anti -CMV 
IgG and IgM, anti -VZV IgG, anti -HIV, and EBV anti -IgG and IgM. Positive tests will have 
follow-up/ confirmatory testing as clinically indicated to assess for active infection.  
5.1.8  If female of child -bearing potential: serum pregnancy test within 14 days of Cycle 1 Day 
1. 
5.1.9  Subjects will have bone marrow aspirate and biopsy with samples sent for differ ential, 
morphology, and flow cytometry for MRD within 90 days prior to Cycle 1 Day 1 , so long 
as there has been no intervening CLL therapy.  
5.1.10  Subjects will have prognostic factors characterized on blood or bone marrow, including 
presence of cytogenetic abno rmalities (chromosome analysis and FISH for 13q -, +12, 
11q-, and 17p -), Immunoglobulin gene heavy chain variable region (IGVH) gene 
mutation status, and expression of ZAP -70 and CD38.  If already known, ZAP -70 and 
IGVH prognostic factors do not need to be reevaluated since they are not expected to 
change.  
5.1.11  Disease staging to include CT scan or MRI as clinically indicated (typically including 
chest, abdomen, pelvis to measure non -palpable lymph nodes) within the last 60 days 
prior to Cycle 1 Day 1 if there ha s been no intervening CLL treatment.  Any appropriate 
radiological examinations should be performed as clinically indicated.  
5.1.12  Research Tests:  peripheral blood and serum collection for one or more of the following 
(i) Leukemia cell immunophenotype, (ii) T and B cell immune response, (iii) plasma 
cytokine levels. (see Correlative Studies Section 5.9).  
 
5.2 To be completed on Day 1 of all Cycles  
5.2.1  Complete history and physical examination including vital signs (blood pressure, heart 
rate, temperature, weight) and organ measurements (i.e., lymph nodes, spleen, liver).  
5.2.2  Current medications will be recorded in the subject's medical record but not captured in 
case report forms.  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 33 of 59 5.2.3  Adverse events assessment and grading per patient reporting.  
5.2.4  Standard laboratory examinations: hematology (CBC w/differential), comprehensive 
metabolic panel (Na+, Cl -, K+, CO2, BUN, Creatinine, Glucose, Ca2+, total protein, 
albumin, total bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium, 
uric ac id, LDH. Also: amylase; lipase.  
5.2.5  Blood collection for correlative studies.  
5.2.6  Pre-medications:  Recommendations are in section 4.3.  
5.2.7  ECG prior to UC -961 infusion.  
5.2.8  Infusion of UC -961 according to section 4.4.  
5.2.9  Post-infusion monitoring: patients will be observe d for at least 1 hour following the 
infusion of UC -961, with continued measurement of blood pressure, pulse, temperature 
every 30 minutes (+/ - 10 minutes).  
5.2.10  ECG within 1 hour following the infusion of UC -961. 
5.2.11  Peripheral blood draw at the end of the infusio n (+/- 10 minutes), including 
comprehensive metabolic panel (CMP), phosphorous, uric acid, LDH.  
5.2.12  Pharmacokinetic (PK) samples are drawn at times points indicated in Pharmacokinetic 
Studies Section 5.8.  
 
5.3 To be completed on Day 2 and Day 8 of each cycle  
5.3.1  Focu sed physical examination including vital signs (blood pressure, heart rate, 
temperature, weight).  
5.3.2  Current medications will be recorded in the subject's medical record but not captured in 
case report forms.  
5.3.3  History, including adverse events assessment and g rading.  
5.3.4  Standard laboratory examinations: hematology (CBC w/differential), comprehensive 
metabolic panel (Na+, Cl -, K+, CO2, BUN, Creatinine, Glucose, Ca2+, total protein, 
albumin, total bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium,  
uric acid, LDH. Also: amylase; lipase.  
5.3.5  Collection of correlative laboratory samples.  
5.3.6  Pharmacokinetic (PK) samples are drawn at times points indicated in Pharmacokinetic 
Studies Section 5.8.  
 
5.4 To be completed on Day 3 and Day 10 of Cycle 1 (and any addition al cycles 
when the dose level changes during intra -patient dose escalation)  
5.4.1  Pharmacokinetic (PK) samples are drawn at times points indicated in Pharmacokinetic 
Studies Section 5.8.  
 
5.5 End of treatment safety assessment 28 days after final infusion (+/ - 3 day ) 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 34 of 59 5.5.1  Complete history and physical examination including vital signs (blood pressure, heart 
rate, temperature, weight) and organ measurements (i.e., lymph nodes, spleen, liver).  
5.5.2  Adverse events grading and reporting  
5.5.3  Standard laboratory examinations: hematology  (CBC w/differential), comprehensive 
metabolic panel (Na+, Cl -, K+, CO2, BUN, Creatinine, Glucose, Ca2+, total protein, 
albumin, total bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium, 
uric acid, LDH. Also: amylase; lipase.  
5.5.4  Collection of correlative lab samples.  
 
5.6 Response Assessment 56 days after final infusion (+/ - 3 day),  
Not all activities are required on the same day.  
5.6.1  Complete history and physical examination including vital signs (blood pressure, heart 
rate, temperatur e, weight) and organ measurements (i.e., lymph nodes, spleen, liver).  
5.6.2  Adverse events grading and reporting.  
5.6.3  Standard laboratory examinations: hematology (CBC w/differential), comprehensive 
metabolic panel (Na+, Cl -, K+, CO2, BUN, Creatinine, Glucose, Ca2+,  total protein, 
albumin, total bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium, 
uric acid, LDH. Also: amylase; lipase.  
5.6.4  Collection of correlative lab samples.  
5.6.5  Serum β2-microglobulin, quantitative T -cell subsets, quantitative immunoglob ulins (IgG, 
IgA, IgM).  
5.6.6  Flow cytometry of peripheral blood for T -cell subtypes and CLL MRD.  
5.6.7  CT scan or MRI of chest, abdomen, and pelvis.  
5.6.8  Bone marrow biopsy if clinically indicated to evaluate complete response / minimal 
residual disease.  
 
5.7 Long term follo w-up 
Every 28 days (+/ - 7 days) for 8 visits then every 56 days (+/ - 7 days), until discontinuation of trial 
participation:  
5.7.1  Complete history and physical examination including vital signs (blood pressure, heart 
rate, temperature, weight)  and organ measure ments (i.e., lymph nodes, spleen, liver).  
5.7.2  Adverse events grading and reporting.  
5.7.3  Standard laboratory examinations: hematology (CBC w/differential), comprehensive 
metabolic panel (Na+, Cl -, K+, CO2, BUN, Creatinine, Glucose, Ca2+, total protein, 
albumin, tot al bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium, 
uric acid, LDH.  
5.7.4  Collection of correlative lab samples.  
 
5.8 Pharmacokinetic (PK) Studies  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 35 of 59 Serum samples will be banked for analysis. ELISA assay will be utilized for serum antibody levels . 
 
Sampling Schedule:  
Cohorts 1 -3 are planned to have intra -patient dose escalation and will have serum samples 
collected for PK analysis at more time points at each new dose level (Tables 5 -7). If at any time 
dose escalation switches to the standard 3+3 dose escalation design without intra -patient dose 
escalation, the serum sample collection for PK analysis will follow the time points listed in Table 
8. 
 
Table 2. PK sampling schedule for Planned Cohort 1 (intra -patient) dose escalation  
Cycle  Day Time point  
1 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 4 hours) post completion of Day 1 infusion  
2 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 8 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 8 hours) post completion of Day 1 infusion  
4 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 36 of 59   
 
Table 3. PK sampling schedule for Planned Cohort 2 (intra -patient) dose escalation  
Cycle  Day Time point  
1 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/- 4 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 4 hours) post completion of Day 1 infusion  
2 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/- 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 8 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 8 hours) post completion of Day 1 infusion  
4 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 37 of 59 Table 4. PK sampling schedule for Planned Cohort 3 (intra -patient) dose escalation  
Cycle  Day Time point  
1 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 46 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 64 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4  8hours) post completion of Day 1 infusion  
10 216 hours (+/ - 84 hours) post completion of Day 1 infusion  
2 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 64 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 64 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 84 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 84 hours) post completion of Day 1 infusion  
3 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 84 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 8 hours) post completion of Day 1 infusion  
4 1 pre-dose 
 
Table 5. PK sampli ng schedule for Planned Cohort 4  (intra -patient) dose escalation  
Cycle  Day Time point  
1 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/- 4 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 4 hours) post completion of Day 1 infusion  
2 
3 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/- 5 minutes) post completion of the infusion  
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 38 of 59 2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 3  48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours  (+/- 8 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 8 hours) post completion of Day 1 infusion  
4 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
1 hour (+/- 5 minutes) post completion of the infusion  
 
Table 6. PK sampling for Cohorts without intra -patient dose escalation  
Cycle  Day Time point  
1 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 48 hours  (+/- 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
10 216 hours (+/ - 4 hours) post completion of Day 1 infusion  
2 1  pre-dose,  
 5-10 minutes prior to the completion of the infusion,  
 30 minutes (+/ - 5 minutes) post completion of the infusion, and  
 1 hour (+/ - 5 minutes) post completion of the infusion  
2 24 hours (+/ - 4 hours) post completion of Day 1 infusion  
8 168 hours (+/ - 4 hours) post completion of Day 1 infusion  
3 1 pre-dose 
4 1 pre-dose  
 
 
Sample Collection and Handling Instructions  
Blood samples (up to 10 ml) will be collected in anti-coagulated tubes at a site distant from the 
infusion for pharmacokinetic evaluation. Samples cannot be drawn from the 2nd lumen of a multi -
lumen catheter through which drug is being administered. The ex act time that the sample is drawn 
along with the exact time that the drug is administered should be recorded.  
 
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 39 of 59 Sample Processing:  Plasma will be isolated in the translational laboratory (Kipps) and stored at 
minus 20 degrees.  
 
Sample Labeling  
Each tube mus t be labeled with the patient’s de -identified study number, and the date and time 
the sample was drawn.  Data should be recorded on the Pharmacokinetic Study Form, which 
must accompany the sample(s).  
 
Sample Shipping Instructions  
Samples may be shipped to third-party vendor for PK analysis. Samples will be shipped as per 
assay manufacturer recommendations.  
 
5.9 Correlative Studies  
Studies will be performed in the Kipps laboratory, to correlate with PK and clinical responses. 
Samples will be taken at baseline/sc reening, during treatment and after treatment. However, not 
all assays will be performed for all time points for all patients, based on sample availability and 
leukemic cell number. Specimens will be banked in the CLL research consortium tissue repository 
(see below).  
 
Assays from patient serum may include:  
 Measurement of cytokine levels (IL2, IL12, and TNFα),  
 Assessment for anti -UC-961 antibody production.  
o Anti-UC-961 antibody production will be assessed on Day 1 of cycles 2, 3, and 4; at 
the end of treatment; and at the time of response assessment (2 months post final UC -
961 dose). If UC -961 interferes with the assay, an additional sample collected during 
follow -up will be assessed.  
o If the binding anti -drug antibody (ADA) is positive,  samples will be banked to assay 
the neutralizing capacity of the ADA.  
 
Isolation of leukemic cells by Ficoll -hypaque separation and assessment, which may include:  
 UC-961 antibo dy binding, ROR1 expression and receptor occupancy  
 ZAP-70, CD38, and Immunoglobulin heavy chain variable region (IgVH) mutation in CLL cells  
 Assessment of down -stream signaling by multiplex qPCR  
 Measurement of Akt and phospho -Akt levels prior to and after  therapy.  
 Expression of co -stimulatory molecules (CD80 and CD86), apoptosis related receptors (CD95 
and DR5), and expression of genes and proteins related to apoptosis, from pre -treated and 
post-treated samples.  
 
5.9.1  Sample Collection Guidelines  
Sampling Sched ule  
Blood sample for correlative studies will be collected at the following time points  and amounts : 
 Screening  
 Day 1 of each cycle : 
o pre-infusion  
o 5-10 minutes prior to the end of the infusion,  
o 30 minutes (+/ - 5 minutes) post infusion  
 Day 2 of each cycle   
 Day 8 of each cycle   
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 40 of 59  End of Treatment visit   
 Response assessment   
 Long -Term Follow -up visits   
 
Sample Collection and Handling Instructions  
Blood samples will be collected in anti-coagulated tubes (up to 20 mL) at a site distant from the 
infusion for pharma cokinetic evaluation. Samples cannot be drawn from the 2nd lumen of a multi -
lumen catheter through which drug is being administered. The exact time that the sample is drawn 
along with the exact time that the drug is administered should be recorded.  
 
Sample  Processing  
Samples will be processed in the translational lab of Dr. Thomas Kipps, with separation of plasma, 
followed by isolation of mononuclear cells or neutrophils by Ficoll or Percoll differential 
centrifugation, respectively.  
 
Sample Labeling  
Each t ube must be labeled with the patient’s study number and the date and time the sample was 
drawn.  Data should be recorded on the Correlative Study Form, which must accompany the 
sample(s).  
 
5.9.2  Specimen Banking  
Patient samples collected for this study will be r etained at the UCSD School of Medicine (Kipps 
Laboratory). Specimens will be stored indefinitely or until they are used up. If future use is denied 
or withdrawn by the patient, best efforts will be made to stop any additional studies and to destroy 
the spe cimens.  Samples will be labeled with the subject’s de -identified study number and 
collection date. The link between study number and medical record number will be viewed over a 
password secured encrypted server -client.   
 
Dr. Kipps will be responsible for reviewing and approving requests for research specimens from 
potential research collaborators outside of UCSD. Collaborators will be required to complete an 
agreement (a Material Transfer Agreement or recharge agreement) that states specimens will 
only be released for use in disclosed research.  Any data obtained from the use of clinical 
specimens will be the property of UCSD for publication and any licensing agreement will be strictly 
adhered to.   
 
The study research coordinator will review the subject's medical record for demographic and 
clinical information pertaining to the subject's general medical history, diagnosis, and outcomes 
of any treatments received.   Samples and data extracted from the subject's medical record will 
be coded with a de -identifie d study number, and the subject's name and identifying information 
will be removed.   A log that links the subject's name and identifiers to the study number will be 
maintained in a secure database distinct from the secure database into which the subject's clinical 
information will be entered  
 
The specimens and their derivatives may have significant therapeutic or commercial value.  The 
Informed Consent form contains this information and informs the subject that there is the potential 
for financial gain by U CSD, the investigator or a collaborating researcher or entity.  
 
The following information obtained from the subject's medical record may be provided to research 
collaborators when specimens are made available:   
UC-961 (Cirmtuzumab)            Confidential  
Amendment 2 dated 6/25/15      Page 41 of 59  Diagnosis  
 Collection time in relation to s tudy treatment  
 Clinical outcome – if available  
 Demographic data  
 
 
6.0 SCHEDULE OF EVENTS
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 42 of 59 Treatment Cycle  Screening  Cycle 1  Cycle 2  Cycle 3  Cycle 4  End of 
Treatment  Response 
Assessment  Long -
Term 
Follow -
up 
Visit Number  1 2  3  4 5 6 7 8 9 10 11 12 13 14 15 16 17  
Visit Day   C1 
D1 C1 
D2 C1 
D3 8 C1 
D8 C1 
D10 8 C2 
D1 C2 
D2 C2 
D8 C3 
D1 C3 
D2 C3
D8 C4 
D1 C4 
D2 C4
D8 28 days 
after last 
dose 56 days after 
last dose  Q28d x8, 
then q56d  
Visit window  ≤ 30 days prior 
to visit 2  ±1d   ±1d  ±1d  ±1d ±1d  ±1d ±1d  ±1d ±3d ±3d ±7d 
Informed Consent  X                  
Eligibility Checklist  X                  
Infectious disease 
screening1  within 56 
days of 
C1D1     
  
            
History and 
Symptoms  X X X   X  X X X X X X X X X X X X 
VS/Ht and Weight  X X     X   X   X   X X X 
Comprehensive PE  X X     X   X   X   X X X 
Focused / 
Abbreviated PE 
(nurse or MD)    X  
X  
 X X  X X  X X    
ECOG Performance 
Status  X X     X   X   X   X X X 
CBC and differential  X X X  
X  
X X X X X X X X X X X X 
Blood chemistry 
panel2 X X 9 X  X  X 9 X X X 9 X X X 9 X X X X X 
PT/aPTT  X                  
ECG3 X X     X   X   X      
Adverse Events 
Screen   X X  X  X X X X X X X X X X X X 
Concomitant 
Medication   X     X   X   X   X X X 
UC-961 
Administration   X     X   X   X      
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 43 of 59 Treatment Cycle  Screening  Cycle 1  Cycle 2  Cycle 3  Cycle 4  End of 
Treatment  Response 
Assessment  Long -
Term 
Follow -
up 
Visit Number  1 2  3  4 5 6 7 8 9 10 11 12 13 14 15 16 17  
Visit Day   C1 
D1 C1 
D2 C1 
D3 8 C1 
D8 C1 
D10 8 C2 
D1 C2 
D2 C2 
D8 C3 
D1 C3 
D2 C3
D8 C4 
D1 C4 
D2 C4
D8 28 days 
after last 
dose 56 days after 
last dose  Q28d x8, 
then q56d  
Visit window  ≤ 30 days prior 
to visit 2  ±1d   ±1d  ±1d  ±1d ±1d  ±1d ±1d  ±1d ±3d ±3d ±7d 
CT scan Chest/ 
Abdomen/ Pelvis 4 within 60 
days of 
C1D1     
  
          X  
Bone marrow 
aspirate and biopsy 5 within 
90 days 
of C1D    
  
          X  
Cytogenetics/FISH 
from bone marrow 
or peripheral blood 6 X    
  
          X  
Quantitative 
inmunoglobulins  7 X                X  
serum β2 -
microglobulin  X                X  
Serum hCG for 
female of child 
bearing potential  within 14 
days of 
C1D1     
  
            
Quantitative T -cell 
subsets  X                X  
Collection of 
Pharmacokinetic and 
/or 
Pharmacodynamic 
Samples 8 X X X X X X X X X X X X X X X X X X 
 
1. Infectious disease screening: HBsAG, anti -HBs, total anti -HBc, IgM anti -HBc), Hep C virus antibody + RNA if antibody positive, anti -CMV IgG 
and IgM, anti-VZV IgG, anti -HIV, and EBV anti -IgG and IgM. Positive tests will have follow -up/confirmatory testing as clinically indicated to 
assess for active infection.  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 44 of 59 2. Chemistry panel to include: comprehensive metabolic panel (Na+, Cl -, K+, CO2, BUN, Creatinine,  Glucose, Ca2+, total protein, albumin, total 
bilirubin, SGPT, SGOT, alkaline phosphatase), phosphorous, magnesium, uric acid, LDH, amylase, and lipase.  
NOTE: amylase and lipase are not measured in long -term follow -up unless clinically indicated.  
3. ECG: To be performed during screening and then prior to and within 1 hour post end of study drug infusion.  
4. Or MRI.   
5. In the case of a CR, an additional bone marrow will be taken two months after patient first achieves CR  
6. Chromosome analysis and FISH Panel to include 11q, 12p, 13q, 17p analysis.  
7. Quantitative IgG, IgA, IgM.  
8. Blood samples are collected for PK, PD, and/or immunogenicity analysis at the following time points of each cycle (refer to s ection 5.8 and 5.9). 
Note: PK collection on Days 3 and 10  may be a dded to additional cycles in cohorts with intra -patient escalation as descr ibed in section 5.8.  
9. Comprehensive metabolic panel, LDH, uric acid, and phosphorous drawn at the completion (+/ - 5 minutes) of UC -961 infusion.  
 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 45 of 59 7.0 Measurement of Effect  
7.1 Safety/tolerability  
7.1.1  Common Terminology Criteria for Adverse Events (CTCAE)  
Analyses will be performed for all patients having received at least one dose of 
study drug. The study will use the CTCAE version 4.0 3 
(http://ctep.cancer.gov/reporting/ctc.html ) for reporting of non -hematologic 
adverse events . 
7.1.2  International Working group for Chronic Lymphocytic Leukemia (IWCLL) criteria for 
hematologic toxicity  
As is the case with  virtually all of the hematological malignancies, an evaluation of 
the hematological toxicity in patients with CLL must consider the high frequency of 
marrow involvement and consequent medullar compromise at the initiation of 
therapy. A substantial proport ion of patients may have hematological parameters 
within the range of Grade 2 hematological toxicity before therapy is given; 
therefore, a modified schema will be used to monitor hematological toxicity in 
patients with CLL. The modified hematological toxic ity schema is displayed:  
 
Modified Grading Scale for Hematological Toxicity in CLL Studies  
Grade1 Decrease in platelets 
(nadir) from pretreatment 
value (%)2 ANC/µl (nadir)3 Hemoglobin4 
0 (not AE)  10%, or above lower limit of 
normal  ≥ 2000  Baseline or higher , or 
above lower limit of 
normal  
1 11-24% ≥ 1500 and < 2000  > 10.0 g/dL and below 
baseline  
2 25-49% ≥ 1000 and < 1500  < 10.0 – 8.0 g/dL and less 
than baseline  
3 50-74%  ≥ 500 and < 1000  < 8.0 – 6.5 g/dL and less 
than baseline  
4 ≥75% or ≤ 25,000/mm3 2 < 500  < 6.5 g/dL and less than 
baseline  
*This schema concurs with the CTEP CTCAE 4.03, except for the platelet values are taken 
from the iwCLL -WG guidelines working group criteria and hemoglobin toxicity modified from 
CTCAE only to account for low baseline values in CLL patients. No hematologic toxicity will be 
registered unless hemoglobin falls below baseline level.  
1 Grades: 1, mild; 2, moderate; 3, severe; 4, life threatening; 5, fatal. Death occurring as a result 
of toxicity at a ny level of decrease from pretreatment will be recorded as a Grade 5.  
2 Treatment will be held for platelet count ≤ 50,000/mm3, even if it does not meet grade 4 criteria 
based on percent decrease. See section 4.6.1 for dose hold/adjustment guidelines.  
3 If baseline ANC is <1,000/μL, neutrophil toxicity cannot be evaluated. In that case, if the 
neutrophil count is less than 1000/μL, it is still recommended to hold therapy until ANC is greater 
than 1000/μL. See section 4.6.1 for dose hold/adjustment guidelin es. 
4 If baseline Hemoglobin is < 8.0, hemoglobin toxicity cannot be evaluated. In that case, if the 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 46 of 59 hemoglobin is less than 8.0, it is still recommended to hold therapy until Hgb is greater than 
8.0. See section 4.6.1 for dose hold/adjustment guidelines.  
7.2 Response Criteria for Patients with Chronic Lymphocytic Leukemia  
Criteria for response will utilize the IWCLL Guidelines for response, which includes clinical, 
hematological, and bone marrow features as outlined below (Hallek et al., 2008) . 
 
Minimal Residual Disease negative : less than 0.01% CLL cell involvement by 4 -color flow 
cytometry of bone marrow aspirate (less than 1 in 10,000 events) and meeting all other criteria 
for complete response.  
 
Complete response: Requires all of the following for a period of at least two months from 
completion of therapy:  
 Absence of significant lymphadenopathy (e.g. >1.5cm in diameter) on physical exam;  
 No hepatomegaly or splenomegaly on physical exam;  
 Absence o f constitutional symptoms;  
 Blood counts corresponding to the following values: Lymphocytes < 4,000/uL, 
polymorphonuclear leukocytes >1500/μL, platelets >100,000/μL, hemoglobin >11.0 g/dL 
(untransfused)  
 Bone marrow aspirate and biopsy must be normocellular for age with <30% of nucleated 
cells being lymphocytes. Lymphoid nodules must be absent. If the marrow is hypocellular, 
a repeat determination should be performed in one month.  
 The marrow should be analyzed by flow cytometry and/or immunohistochemistry to 
demonstrate that the marrow is free of clonal B - CLL cells.  
 A CT scan or MRI documenting absence of significant lymphadenopathy should be 
performed if previously abnormal.  
 Patients who fulfill the criteria for CR with the exception of a persistent cytopeni a that is 
believed to be treatment related will be considered CR with incomplete bone marrow 
recovery (CRi). Additionally, patients who fulfill the criteria of CR with exception of having 
bone marrow lymphoid nodules will be considered a nodular PR.  
 
Parti al response:  Requires at least 2 of the following criteria from group A, and at least one of 
the criteria from group B, and for a period of at least 2 months:  
Group A:  
 ≥50% decrease in peripheral absolute lymphocyte count from pretreatment value, or less 
than 4,000/uL.  
 ≥50% reduction in lymphadenopathy by examination or scan, or less than 1.5cm in size.  
 ≥50% reduction in splenomegaly (cm below costal margin) by examination or scan  
 ≥50% reduction hepatomegaly (total liver span) by examination or scan  
 ≥50% r eduction in marrow infiltrate or B -lymphoid nodules  
Group B:  
 Polymorphonuclear leukocytes ≥1,500/μL or 50% improvement from pre -treatment value;  
 Platelets >100,000/μL or 50% improvement from pre -treatment value;  
 Hemoglobin >11.0 g/dl (un -transfused) or 50%  improvement from pre -treatment value.  
 
Progressive Disease:  Characterized by any one of the following events:  
 ≥50% increase in the products of at least two lymph nodes on two consecutive 
determinations two weeks apart (at least one lymph node must be ≥2 cm); appearance of 
new palpable lymph nodes.  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 47 of 59  ≥50% increase in the size of the liver and/or spleen as determined by measurement below 
the respective costal margin; appearance of palpable hepatomegaly or splenomegaly, 
which was not previously present.  
 An inc rease in the number of blood lymphocytes by 50% or more with at least 5000 B 
lymphocytes per microliter.  
 Transformation to a more aggressive histology (i.e., Richter’s syndrome or prolymphocytic 
leukemia with ≥56% prolymphocytes).  
 During therapy,  patients not fulfilling the above criteria for progressive disease but 
demonstrating a decrease in hemoglobin >2 gm/dL, decrease >50% in platelet or 
granulocyte count will not be rated as progressive disease because these may occur as 
both a consequence of therapy.  A bone marrow biopsy in such settings is strongly 
encouraged. Furthermore, during therapy, patients with progressive lymphocytosis but not 
any other findings of hemoglobin, platelet count, lymph node size, or spleen size meeting 
criteria for progressive d isease will not be rated as progressive disease as agents that 
target the akt pathway have been demonstrated to induce a redistributive lymphocytosis 
as part of the mechanism of action (Byrd et al., 2013) . 
 After  treatment, The progression of any cytopenia (unrelated to autoimmune cytopenia), 
as documented by a decrease of Hb levels by more than 20 g/L (2 g/dL) or to less than 
100 g/L (10 g/dL), or by a decrease of platelet counts by more than 50% or to less than 
100 × 109/L (100 000/μL), which occurs at least 3 months after treatment, defines disease 
progression, if the marrow biopsy demonstrates an infiltrate of clonal CLL cells.  
 
Stable Disease:  Patients who do not fulfill the criteria for complete or partial re sponse as defined 
above but do not exhibit progressive disease will be considered as having stable disease.  
7.2.1  Progression -Free Survival  
Progression -free survival (PFS) is defined as the duration of time from start of treatment 
until objective tumor progression or death.  
 
 
8.0 ADVERSE EVENTS  
 
An adverse event (AE) is any untoward medical occurrence in a patient receiving study treatment 
and which does not necessarily have a causal relationship with this treatment. An AE can 
therefore be any unfavorable an d unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an experimental intervention, whether 
or not related to the intervention.  
8.1 Adverse Event Monitoring  
Adverse event data collection and reporting, which are required as part of every clinical trial, are 
done to ensure the safety of subjects enrolled in the studies as well as those who will enroll in 
future studies using similar agents. Adverse events are r eported in a routine manner at scheduled 
times during a trial. Additionally, certain adverse events must be reported in an expedited manner 
to allow for optimal monitoring of patient safety and care.  
 
 
 
As far as possible, each adverse event should be eva luated to determine:  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 48 of 59  duration (start and end dates)  
 severity (grade)  
 seriousness  
 relationship to study agent  
 action taken (i.e., none, study agent modification, medical intervention)  
 outcome (i.e., resolved without sequelae, resolved with sequelae, ongoing ) 
 
All patients experiencing an adverse event, regardless of its relationship to study drug, will be 
monitored until:  
 the adverse event resolves or the symptoms or signs that constitute the adverse event 
return to baseline;  
 any abnormal laboratory values have returned to baseline;  
 there is a satisfactory explanation other than the study drug for the changes observed; or  
 death.  
8.2 Severity  
All non -hematologic adverse events will be graded according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03. The CTCAE v4.03 is available at 
http://ctep.cancer.gov/reporting/ctc.html . All hematologic adverse events will be graded according 
to the modified iwCLL criteria.  
 
If no grading is available, the severity of an AE is graded as follows:  
Mild (grade 1):  the event causes discomfort without disruption of normal daily activities.  
Moderate (grade 2):  the event causes discomfort that affects normal daily act ivities.  
Severe (grade 3):  the event makes the patient unable to perform normal daily activities or 
significantly affects his/her clinical status.  
Life-threatening (grade 4):  the patient was at risk of death at the time of the event.  
Fatal (grade 5):  the e vent caused death.  
8.3 Seriousness  
A “serious” adverse event is defined in regulatory terminology as any untoward medical 
occurrence that:  
1. Results in death.  
If death results from (progression of) the disease, the disease should be reported 
as event (SAE) itsel f. 
2. Is life -threatening.  
(the patient was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe).  
3. Requires in -patient hospitalization or prolongation of existing hospitalization for ≥ 
24 hours.  
4. Results in persistent or significant disability or incapacity.  
5. Is a congenital anomaly/birth defect  
6. Is an important medical event  
Any event that does not meet the above criteria, but that in the judgment of the 
investigator jeopardizes the patient, may be considered for reporting as a serious 
adverse event. The event may require medical or surgical intervention to prevent 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 49 of 59 one of the outcomes listed in the definition of “Serious Adverse Event“.  
For example: allergic bronchosp asm requiring intensive treatment in an 
emergency room or at home; convulsions that may not result in hospitalization; 
development of drug abuse or drug dependency.  
8.4 Relationship  
Attribution categories for adverse events in relationship to protocol therapy are as follows:  
Definite – The AE is clearly related  to the study treatment.  
Probable – The AE is likely related to the study treatment.  
Possible – The AE may be related  to the study treatment.  
Unlikely – The AE is doubtfully related to the study treatment . 
Unrelated – The AE is clearly NOT related  to the study treatment.  
8.5 Prior experience  
Expected events are those that have been previously identified as resulting from administration 
of the agent. An adverse event is considered unexpected, for expedited repo rting purposes only, 
when either the type of event or the severity of the event is not listed in the toxicities listed in the 
agent information section of this protocol.  
8.6 Reporting Requirements for Adverse Events  
8.6.1  Expedited Reporting  
 The Principal Investigator  must be notified within 24 hours of learning of any 
serious adverse events , regardless of attribution, occurring during the study 
or within 30 days of the last administration of the study drug.  
 The UCSD Human Research Protections Program (HRP P) must be notified 
within 10 business days  of “any unanticipated problems involving risk to 
subjects or others” (UPR).  
The following events meet the definition of UPR:  
1. Any serious event (injuries, side effects, deaths or other problems), 
which in the opin ion of the Principal Investigator was unanticipated, 
involved risk to subjects or others, and was possibly related to the 
research procedures.  
2. Any serious accidental or unintentional change to the IRB -approved 
protocol that alters the level of risk.  
3. Any de viation from the protocol taken without prior IRB review to 
eliminate apparent immediate hazard to a research subject.  
4. Any new information (e.g., publication, safety monitoring report, 
updated sponsor safety report), interim result or other finding that 
indicates an unexpected change to the risk/benefit ratio for the 
research.  
5. Any breach in confidentiality that may involve risk to the subject or 
others.  
6. Any complaint of a subject that indicates an unanticipated risk or that 
cannot be resolved by the Princip al Investigator.  
 The FDA should be notified within 7 calendar days  of any unexpected fatal or 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 50 of 59 life-threatening adverse event with possible relationship to study drug, and 15 
calendar days  of any adverse event that is considered: 1) serious, 2) 
unexpected, and 3) at least possibly related to study participation.  
8.6.2  Routine Reporting Requirements  
 The UCSD HRPP will be notified of any adverse events that are not 
unanticipated problems involving risk to subjects or others (non -UPRs) at the 
time of the annual Conti nuing Review.  
 The FDA will be notified of all non -serious adverse events annually at the time 
of the annual report.  
 
9.0 AGENT INFORMATION  
9.1 UC-961 (Cirmtuzumab)  
Please refer to Investigator’s Brochure for more comprehensive information.  
 
Structure: Monoclonal antibody  
 
Supplied by:  UC-961 will be produced at Pacific GMP (San Diego, CA) in compliance with cGMP 
standards.  
 
Formulation  
The agent is supplied as a liquid formulation at a concentration of 40 mg/ml protein, with 7.2 to 
7.8 mL/vial. Each ml of the form ulation contains 40 mg UC -961, 14.7 mg sodium citrate, 10 mg 
trehalose, 216 µg Polysorbate 80, 15 µg sodium EDTA and adjusted to pH 5.2 ± 0.2.  
 
UC-961 will be filled into 10ml clear borosilicate Type 1 glass vials with 20 mm grey butyl 
siliconized rubber s topper and 20 mm aluminum royal blue flip off seals.  
 
Storage  
UC-961 is to be kept refrigerated (2 -8C) until use, in single use vials.  
 
Solution Preparation  
To prepare the agent for administration, it will be dissolved in normal saline to the following final 
concentrations:  
 100 µg/mL for cohort s 1 and 2 (or doses 15 µg/kg to 240 µg/kg);  
 500 µg/mL for cohorts 3 and 4 (or dose 500 µg/kg to 2 mg/kg)  
 1 mg/mL for cohort 5 (or dose 4 mg/kg)  
 2 mg/mL for cohort 6 (or dose 8 mg/kg)  
 4 mg/mL for cohorts 7 and 8 (or doses 16mg/kg and 20 mg/kg)   
 
Administration  
The drug will be administered by intravenous infusion with infusion rate according to section 4.4.  
     
Toxicities   
No toxicities have been established, as this is a first -in-human study. There is no off -target binding 
identified in initial preclinical assays. Infusion reaction, fluid retention, tumor lysis syndrome, and 
immunogenicity are possible class effects of mono clonal antibody therapy. Depletion of precursor 
B cells and B cell lymphopenia are possible as well. Other ROR1 antibodies, distinct from UC -
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 51 of 59 961, have demonstrated binding to pancreatic islet cells and adipose tissue (Hudecek et al., 
2010) . Glucose levels and body weight will therefore be monitored.  
 
 
10.0 STATISTICAL CONSIDERATIONS  
10.1 Study Design/Study Endpoints  
This is a phase I study of UC -961, a humanized anti -ROR1 monoclonal antibody, for patients with 
relapsed or refractory CLL.  
 
The primary endpoints are the rate of dose limiting toxicities (DLTs) and the maximum tolerated 
dose or biologically active dose  of UC961 . 
 
Secondary endpoints include treatment -emergent adverse events, the complete/overall resp onse 
rate (2008 iwCLL criteria, which is based on reduction in leukemia count, reduction in 
lymphadenopathy and splenomegaly, and improvement in BM function), and the progression -free 
survival in patients treated with repeated doses of UC -961. 
 
Exploratory  endpoints include circulating UC-961 levels in peripheral blood,  antibody production 
against UC -961, leukemia cell immunophenotype, leukemia cell akt/ phospho -akt levels, and 
plasma cytokine levels.  
10.2 Statistical Design  
As this is a hypothesis testing study  for safety, no formal sample size or power calculations will 
be made. The dose levels will start from 15 µg/kg and increase as per table in section 4.1.  
In order to start at low doses of UC -961 to evaluate for acute toxicities like tumor lysis syndrome, 
but not expose large numbers of patients to potentially sub -therapeutic doses that do not saturate 
circulating ROR1 (and therefore may not affect nodal or bone marrow compartments) , patients in 
the first 4 cohorts will have intra -patient dose escalation. If  there is a grade  ≥ 2 adverse  event , in 
cohorts with intra -patients dose escalation, then the dose escalation scheme will switch to the 
standard 3 + 3 design without intra -patient dose escalation, starting at the dose at which the grade  
≥ 2 toxicity  occurr ed. Otherwise, cohorts 5 to 7 will utilize a standard 3+3 dose escalation design. 
This design is based on phase 1 design guidance by the NCI (Le Tourneau et al. , 2009) .  All 
adverse events should be considered relevant unless the event can clearly be determined to be 
unrelated to the drug, e.g., clearly related to disease progression.  
 
Dose Escalation Rules  
For the first 4 cohorts with intra -patient dose escalation, three subjects will be enrolled. Each 
subject will be treated according to the dose levels in Table 1. If there is no grade 2 or above 
adverse reaction in the first 56 days starting from the first infusion of UC961, we will escalate to 
the next cohort. If ther e is one or more grade 2 or above adverse event, the study will switch to a 
standard 3+3 design. All adverse events should be considered relevant unless the event can 
clearly be determined to be unrelated to the drug, e.g., clearly related to disease progr ession.  
 
After a standard 3+3 design begins, a  minimum of three subjects will be treated at each dose 
level. All three subjects in a cohort will be evaluated for DLT in the defined DLT evaluation period 
(within 28 days of starting study treatment) before e nrollment of subjects at the next dose level 
may begin. For all dose levels, if no DLTs are observed during the evaluation period among the 
three treated patients, escalation to the next dose level may begin. If a DLT is observed in one of 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 52 of 59 the first three subjects in the cohort, the cohort will be expanded to six subjects. If zero or one of 
six subjects in the cohort experiences a DLT within the evaluation period, escalation to the next 
dose level will occur. If a DLT is seen in two or more subjects in a co hort, escalation will be 
stopped and the Maximum Tolerated Dose (MTD) will be considered to have been exceeded. The 
next lower dose will be considered as MTD if six patients have already been treated at that dose. 
Otherwise if only three patients were trea ted at the next lower dose, then an additional three 
patients should be enrolled at the next lower dose level for a total of six patients. If zero or one 
has DLTs among the 6 patients, then this dose is declared as MTD. Otherwise, there is further 
de-escal ation according to the same scheme. As a result, the MTD is the highest dose where at 
most one -sixth of the patients developed DLT.  
 
In addition, an expansion cohort of 6 patients will be added at the recommended dose (MTD or 
biologically active dose) once  that dose has been determined.  
 
10.2.1  Probability of Dose Escalation  
For the first 3 cohorts, we will escalate according to table 1 as long as there is no grade 2 or above 
adverse reaction occurred. After we switch to a standard 3+3 design, there will be two possible 
outcomes that would permit escalation to occur: (1) no DL T observed in the first three subjects; 
or (2) one DLT observed in the first three subjects, followed by no DLT observed in three additional 
subjects at the same dose level.  The following probabilities of dose escalation (Table 6) are 
calculated as the sum  of the binomial probabilities of the two possible outcomes.   For example, 
when the underlying DLT rate is no more than 20%, the probability of dose escalation will be over 
71%.  
 
Table 6. Probability of dose escalation  
Underlying DLT Rate  Probability  
of Dose Escalation  
10% 91% 
20% 71% 
30% 49% 
40% 31% 
 
10.2.2  Determination of the MTD  
Definition of MTD: The maximum tolerated dose (MTD) is defined as the highest dose studied at 
which no more than one in six patients experience a DLT. However, the final determination will 
also take into account any cumulative or delayed toxicity (e.g. an adverse event that occurs in 
later cycles). Accrual is suspended when a cohort of three subjects has been enrolled until toxicity 
data for that cohort for the DLT evaluation period have been reported, or when the study endpoints 
have been met.  
 
At the MTD or biologically active dose, an expansion cohort of an additional 6 patients will be 
enrolled, again evaluated after each 3 for DLTs.   
10.3 Evaluable Cohor t and Subject Replacement  
The trial may be completed after 33 patients have been enrolled, based on 8 cohorts with a total 
of 12 patients at the MTD/biologically active dose. If the dose escalation switches to standard 3+3 
design, then up to 78 patients wi ll be enrolled, based on 3 -6 patients per cohort for 12 cohorts (if 
all dose levels require cohorts without intra -patient  escalation), and a total of 12 patients at the 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 53 of 59 MTD/biologically active dose. A subject will be considered evaluable for assessment of DLT if the 
subject receives at least 2 doses of UC -961 and completes the safety follow -up through the DLT 
evaluation period, or the subject experiences a DLT at any time during the DLT evaluation period. 
Any non -evaluable subject will be replaced in the sa me dose cohort to complete the number of 
evaluable subjects for the MTD analysis.  
 
The Safety population will include all subjects who receive any treatment of UC -961. The Safety 
population will be used to evaluate baseline characteristics as well as all d escriptive endpoints for 
safety.  
10.4 Statistical Analysis  
The adverse events from the treatment beginning to two months after treatment completion will 
be recorded. Incidence of adverse events will be summarized by event type, grade and body 
system.  Particularly, the rates of infusion reactions, major infection and grade 3 or above non -
infection adverse events will be reported.  
 
Secondary endpoints.  
The following will be reported overall and by dose cohort:  as available, median progression -free 
survival will be estimated using the Kaplan -Meier method.   Clinica l activity will be assessed based 
on iwCLL criteria, assessed from baseline visit to the response assessment visit.  
  
Exploratory endpoints to be analyzed include the following mechanism of action studies, by dose 
cohort:  
1. ROR1 receptor density on circulati ng bulk tumor cells and stem cells (flow assays)  
2. Plasma pharmacokinetics of UC -961 levels  
3. Level of circulating antibodies against UC -961 
4. Multiplexed assay of focused CLL signaling pathways via qPCR array and targeted 
sequencing.  
5. ROR1 related protein assays  via western blot and quantitative proteomics.  
 
PK/PD studies using non -compartmental models will be reported based on assays 1 -3. Assays 4 
and 5 will be assessed at baseline and the response assessment visit. Within patient changes 
will be assessed for st atistical significance at the 5% level, using t -tests on appropriately 
transformed data or non -parametric tests as necessary.  Comparisons across dose cohorts will 
use generalized linear models or anova.  
 
Standard laboratory examinations including hematolo gy, comprehensive metabolic panel, etc 
(see section 5.0) will be performed before, during and after the treatment. We will test if the 
average level of these measurements after the treatment is higher or lower than the pre -treatment 
level by a paired t -test at 5% significance level. For each marker, a Wilcoxon rank sum test will 
be used to assess the association of a baseline level or changes from baseline to the last 
measurement against tumor response status at the time of the response assessment visit.  
 
The overall response rate, complete response rate, MRD negative rate will also be reported, 
overall and by dose cohort.  
 
All statistical analyses will be at the 5% significance level using 2 -sided tests.  
10.5 Exposure -response modeling  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 54 of 59 Following the FDA Guidanc e for Industry on Exposure -Response Relationships , exposure -
response modeling of effectiveness and toxicity will be conducted as part of the secondary 
endpoint evaluation.  The goal of these analyses will be to identify a dose -response relationship, 
if any , between exposure to UC -961 and clinical response (effectiveness) or adverse events 
(toxicity).   Dose of UC -961 will be defined using both administered dose and PK/PD derived 
measures, as described in detail below.  
10.5.1  Exposure -response modeling of effective ness.  
The primary response variable will be the overall response rate, defined as CR, PR or PR with 
persistent lymphocytosis at final assessment (section 7.2).    
Secondary response variables will include:  
 the average percent reduction in the pretreatment lymphocyte count,  
 the average sum  of the products of lymph nodes,  
 the percent of patients experiencing sustained improvement in cytopenias, defined as 
improvement by more than 50% of baseline value, or h emoglobin level higher than 11 g 
per deciliter, an absolute neutrophil count higher than 1500 cells per cubic millimeter, or 
a platelet count higher than 100,000 cells per cubic millimeter, as measured at both end 
of treatment and final response assessment . 
Two analyses will be conducted using two different primary exposure variables. The first 
analysis will be by  actual total doses received .  A second analysis will use the primary PK 
exposure variable of AUC 0-t ,defined as the area under the concentration versus time curve from 
time zero to the sampling time at the last quantifiable concentration (C t), calculated by the linear 
trapezoidal rule from a two -compartment PK model.   This last quantifiable concentration will be 
cycle 4 day 1, prior to start of in fusion.  The AUC 0-t will be computed by the third -party vendor for 
PK.   Other potential secondary exposure variables considered will be ROR1 receptor 
occupancy measured during treatment.  
 
The primary covariates will be age > 70 years, RAI stage, presence of Del 17p  or Del 11q, 
number of prior therapies, mutational status, ZAP -70 status, baseline presence of nodes > 5 
cm, baseline myelotoxicity ( Grade  3 neutropenia, anemia, or thrombocytopenia), and baseline 
ECOG performance status >0 . 
 
The modeling approach will be logistic regression of response (or alternatively a GLM for the 
appropriately transformed outcome of percent reduction), using the primary exposure variable 
and including covariates.  Covariates will be screened one at a time for association with 
response using chi -squared tests; variables significant at the 20% level will be retained in the 
final model. A dose -response relation between UC -961 exposure and response will be tested for 
using a one sided test at the 5% significanc e level.  A positive statistical association will provide 
preliminary causal evidence of efficacy.  Lack of association may be due to small sample sizes 
at the biologically effective dose, in this Phase I study.  
10.5.2  Exposure -response modeling of toxicity.  
The primary response variable will be the overall rate of grade 3 or higher adverse events 
(Section 8) of any attribution.     
 
Secondary response variables will include:  
 The overall rate of grade 1 or higher adverse events.  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 55 of 59  Individual analysis of any categor y of adverse event which occurs at higher than 50% 
rate (others will be too few for individual analysis at the small anticipated sample 
size)  
As in the efficacy models, two analyses will be conducted using two different primary exposure 
variables. The firs t analysis will be by actual total doses received .  The second analysis will use 
the primary PK exposure variable of AUC 0-t , defined as in the efficacy analysis.  
The primary covariates will be age > 70 years, RAI stage, presence of Del 17p or Del 11q, 
number of prior therapies, mutational status, ZAP -70 status, baseline presence of nodes > 5 
cm, baseline myelotoxicity (Grade   3 neutropenia, anemia, or thrombocytopenia), and 
baseline ECOG performance status >0.  
 
The modeling approach will be logistic regr ession, using the primary exposure variable and 
including covariates.  Covariates will be screened one at a time for association with response 
using chi -squared tests; variables significant at the 20% level will be retained in the final model. 
A dose -respo nse relation between UC -961 exposure and response will be tested for using a 
one sided test at the 5% significance level.    
 
11.0 STUDY MANAGEMENT  
11.1 Conflict of Interest  
Any investigator who has a conflict of interest with this study (patent ownership, royalties , or 
financial gain greater than the minimum allowable by their institution, etc.) must have the conflict 
reviewed according to UCSD conflict of interest policy.  
11.2 Institutional Review Board (IRB) Approval and Consent  
The IRB should approve the consent form and protocol prior to any study -related activities.  It is 
expected that the IRB will have the proper representation and function in accordance with 
federally mandated regulations.  
 
In obtaining and documenting info rmed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to Good Clinical Practice (GCP) and to 
ethical principles that have their origin in the Declaration of Helsinki.  
  
Before recruitment and enrollme nt onto this study, the patient will be given a full explanation of 
the study and will be given the opportunity to review the consent form. Each consent form must 
include all the relevant elements currently required by the FDA Regulations and local or stat e 
regulations. Once this essential information has been provided to the patient and the investigator 
is assured that the patient understands the implications of participating in the study, the patient 
will be asked to give consent to participate in the stu dy by signing an IRB -approved consent form.  
 
Prior to a patient’s participation in the trial, the written informed consent form should be signed 
and personally dated by the patient and by the person who conducted the informed consent 
discussion.  
11.3 Subject Da ta Protection  
In accordance with the Health Information Portability and Accountability Act (HIPAA), subjects 
who have provided written informed consent must also sign a subject authorization to release 
medical information to the study Sponsor and allow a r egulatory authority, or Institutional Review 
Board access to subject’s medical information relevant to the study.  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 56 of 59 11.4 Data and Safety Monitoring  
In addition to adverse event monitoring and clinical oversight by the principal investigator and co -
investigators, quality assurance of the study will be performed by the clinical trials office internal 
monitor. Monitoring intervals will be dependent upon the number of patients enrolled and the 
complexity of the study.  
 
This study will also use the UCSD Moores Cancer Center Data Safety and Monitoring Board 
(DSMB) to provide oversight in the event that this treatment approach leads to unforeseen 
toxicities. Data from this study will be reported after every 6 patients or sooner if required for 
clinical study stopping rul es (Section 4.9), and will include:  
 
1) the protocol title, IRB protocol number, and the activation date of the study.  
2) the number of patients enrolled to date  
3) the date of first and most recent patient enrollment  
4) a summary of all adverse events r egardless of grade and attribution   
5) a response evaluation for evaluable patients when available  
6) a summary of any recent literature that may affect the ethics of the study.  
 
11.5 Record Retention  
Study documentation includes all Case Report Forms, data c orrection forms or queries, source 
documents, Sponsor -Investigator correspondence, monitoring logs/letters, and regulatory 
documents (e.g., protocol and amendments, IRB correspondence and approval, signed patient 
consent forms).  
 
Source documents include a ll recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research study.  
 
Government agency regulations and directives require that the study investigator must retain all 
study documentation pertaining to the conduct of a clinical trial. In the case of a study with a drug 
seeking regulatory approval and marketing, these documents shall be retained for at least two 
years after the last approval of marketing a pplication in an International Conference on 
Harmonization (ICH) region. In all other cases, study documents should be kept on file until three 
years after the completion and final study report of this investigational study.  
11.6 Obligations of Investigators  
The Principal Investigator is responsible for the conduct of the clinical trial at the site in accordance 
with Title 21 of the Code of Federal Regulations and/or the Declaration of Helsinki. The Principal 
Investigator is responsible for personally overseeing  the treatment of all study patients. The 
Principal Investigator must assure that all study site personnel, including sub -investigators and 
other study staff members, adhere to the study protocol and all FDA/GCP/NCI regulations and 
guidelines regarding cli nical trials both during and after study completion.  
 
The Principal Investigator at each institution or site will be responsible for assuring that all the 
required data will be collected and entered onto the Case Report Forms. Periodically, monitoring 
visits will be conducted and the Principal Investigator will provide access to his/her original records 
to permit verification of proper entry of data. At the completion of the study, all case report forms 
will be reviewed by the Principal Investigator and wil l require his/her final signature to verify the 
accuracy of the data.  
 
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 57 of 59   
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 58 of 59 12.0 REFERENCES  
 
1. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol . 
2011;29 (5):544 -550. 
2. Hallek M, Fischer K, Fingerle -Rowson G et al. Ad dition of rituximab to fludarabine and 
cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open -
label, phase 3 trial. Lancet . 2010;376 (9747):1164 -1174.  
3. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukem ia. Hematology 
Am Soc Hematol Educ Program . 2011;2011 (110 -118. 
4. Goede V, Fischer K, Busch R et al. Obinutuzumab plus Chlorambucil in Patients with CLL 
and Coexisting Conditions. N Engl J Med . 2014  
5. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK wi th Ibrutinib in Relapsed Chronic 
Lymphocytic Leukemia. N Engl J Med . 2013  
6. Woyach JA, Furman RR, Liu TM et al. Resistance Mechanisms for the Bruton's Tyrosine 
Kinase Inhibitor Ibrutinib. N Engl J Med . 2014  
7. Fukuda T, Chen L, Endo T et al. Antisera indu ced by infusions of autologous Ad -CD154 -
leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl 
Acad Sci U S A . 2008;105 (8):3047 -3052.  
8. Broome HE, Rassenti LZ, Wang HY et al. ROR1 is expressed on hematogones (non -
neoplas tic human B -lymphocyte precursors) and a minority of precursor -B acute 
lymphoblastic leukemia. Leuk Res . 2011;35 (10):1390 -1394.  
9. Hudecek M, Schmitt TM, Baskar S et al. The B -cell tumor -associated antigen ROR1 can 
be targeted with T cells modified to exp ress a ROR1 -specific chimeric antigen receptor. 
Blood . 2010;116 (22):4532 -4541.  
10. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase -
like domain. J Biol Chem . 1992;267 (36):26181 -26190.  
11. Matsuda T, Nomi M, Ikeya M  et al. Expression of the receptor tyrosine kinase genes, Ror1 
and Ror2, during mouse development. Mech Dev . 2001;105 (1 -2):153 -156. 
12. Zhang S, Chen L, Wang -Rodriguez J et al. The onco -embryonic antigen ROR1 is 
expressed by a variety of human cancers. Am J Pathol . 2012;181 (6):1903 -1910.  
13. Cui B, Zhang S, Chen L et al. Targeting ROR1 inhibits epithelial -mesenchymal transition 
and metastasis. Cancer Res . 2013;73 (12):3649 -3660.  
14. Widhopf GFn, Cui B, Ghia EM et al. ROR1 can interact with TCL1 and enhanc e 
leukemogenesis in Emu -TCL1 transgenic mice. Proc Natl Acad Sci U S A . 2014;111 
(2):793 -798. 
15. Agoram BM. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose 
selection in first -in-human trials of high -risk biologics. Br J Clin Pharmacol . 2009;67 
(2):153 -160. 
16. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of 
chronic lymphocytic leukemia: a report from the International Workshop on Chronic 
Lymphocytic Leukemia updating the National Cancer Institute -Working Group 1996 
guidelines . Blood . 2008;111 (12):5446 -5456.  
17. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J 
Natl Cancer Inst . 2009;101 (10):708 -720. 
 
  
UC-961 (Cirmtuzumab)            Conf idential  
Amendment 2 dated 6/25/15      Page 59 of 59 13.0 APPENDICES  
13.1 Appendix A. Performance Status  
 
PERFORMANCE STATUS CRITER IA 
ECOG Performance Status  
 
Score  Description  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up 
and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
 
 
 
 
 
 
 
 
 
 